| 1 |
Milanetto AC, Gais Zürcher AL, David A, Fassan M, Pasquali C. Pancreatic Neuroendocrine Neoplasms Larger than 4 cm: A Retrospective Observational Study of Surgery, Histology, and Outcome. J Clin Med 2023;12. [PMID: 36902627 DOI: 10.3390/jcm12051840] [Reference Citation Analysis]
|
| 2 |
Scheufele F, Friess H. Neuroendokrine Tumoren des Pankreas. Im Fokus Onkologie 2023;26:14-19. [DOI: 10.1007/s15015-022-3030-0] [Reference Citation Analysis]
|
| 3 |
Zhang L, Jin R, Yang X, Ying D. A population-based study of synchronous distant metastases and prognosis in patients with PDAC at initial diagnosis. Front Oncol 2023;13:1087700. [PMID: 36776324 DOI: 10.3389/fonc.2023.1087700] [Reference Citation Analysis]
|
| 4 |
Jayasekera M, Sartin S, Bhargava P. Ga-68 DOTATATE PET/CT in a patient with Zollinger-Ellison syndrome. Radiol Case Rep 2023;18:1046-8. [PMID: 36684643 DOI: 10.1016/j.radcr.2022.12.038] [Reference Citation Analysis]
|
| 5 |
Marcal LP, Chuang HH, Tran Cao HS, Halperin DM. Pancreatic Neuroendocrine Tumors. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00014-8] [Reference Citation Analysis]
|
| 6 |
Sira L, Zsíros N, Bidiga L, Barna S, Kanyári Z, Nagy EB, Guillaume N, Wild D, Rázsó K, Andó S, Balogh I, Nagy EV, Balogh Z. Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies. Front Endocrinol (Lausanne) 2023;14:1095815. [PMID: 36923225 DOI: 10.3389/fendo.2023.1095815] [Reference Citation Analysis]
|
| 7 |
Huang XT, Xie JZ, Chen LH, Cai JP, Chen W, Liang LJ, Zhang N, Yin XY. Values of debulking surgery for unresectable well-differentiated metastatic pancreatic neuroendocrine tumors: a comparative study. Gastroenterol Rep (Oxf) 2023;11:goad010. [PMID: 36911142 DOI: 10.1093/gastro/goad010] [Reference Citation Analysis]
|
| 8 |
Marc B, Monino L, Rimbas M. EUS-guided intra-tumoral therapies. Best Pract Res Clin Gastroenterol 2022;60-61:101817. [PMID: 36577536 DOI: 10.1016/j.bpg.2022.101817] [Reference Citation Analysis]
|
| 9 |
Sacewicz-Nowak M, Siejka A. Acute Kidney Injury with Severe Hypokalemia. Am J Med 2022;135:e427-9. [PMID: 36058307 DOI: 10.1016/j.amjmed.2022.08.015] [Reference Citation Analysis]
|
| 10 |
Gaspar TB, Lopes JM, Soares P, Vinagre J. An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms. Endocrine-Related Cancer 2022;29:R191-R208. [DOI: 10.1530/erc-22-0166] [Reference Citation Analysis]
|
| 11 |
Kurita Y, Kobayashi N, Hara K, Mizuno N, Kuwahara T, Okuno N, Haba S, Tokuhisa M, Hasegawa S, Kubota K, Nakajima A, Ichikawa Y. Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options. Cancers (Basel) 2022;14. [PMID: 36428761 DOI: 10.3390/cancers14225669] [Reference Citation Analysis]
|
| 12 |
Lu Z, Li T, Liu C, Zheng Y, Song J. Development and validation of a survival prediction model and risk stratification for pancreatic neuroendocrine neoplasms. J Endocrinol Invest 2022. [DOI: 10.1007/s40618-022-01956-7] [Reference Citation Analysis]
|
| 13 |
Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J. Preclinical Models of Neuroendocrine Neoplasia. Cancers (Basel) 2022;14. [PMID: 36428741 DOI: 10.3390/cancers14225646] [Reference Citation Analysis]
|
| 14 |
So H, Ko SW, Shin SH, Kim EH, Son J, Ha S, Song KB, Kim HJ, Kim MH, Park DH. Comparison of EUS-guided ablation and surgical resection for nonfunctioning small pancreatic neuroendocrine tumors: a propensity score-matching study. Gastrointest Endosc 2022:S0016-5107(22)02141-1. [PMID: 36400239 DOI: 10.1016/j.gie.2022.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 15 |
Chen H, Li Z, Hu Y, Xu X, Ye Z, Lou X, Zhang W, Gao H, Qin Y, Zhang Y, Chen X, Chen J, Tang W, Yu X, Ji S. Maximum Value on Arterial Phase Computed Tomography Predicts Prognosis and Treatment Efficacy of Sunitinib for Pancreatic Neuroendocrine Tumours. Ann Surg Oncol 2022. [DOI: 10.1245/s10434-022-12693-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 16 |
Shi XB, Deng WX, Jin FX. Bone marrow metastatic neuroendocrine carcinoma with unknown primary site: A case report and review of the literature. World J Clin Cases 2022; 10(30): 11074-11081 [DOI: 10.12998/wjcc.v10.i30.11074] [Reference Citation Analysis]
|
| 17 |
Scheufele F, Friess H. Diagnostik und Therapie neuroendokriner Tumoren des Pankreas. Gastro-News 2022;9:34-39. [DOI: 10.1007/s15036-022-3115-9] [Reference Citation Analysis]
|
| 18 |
Ciobanu OA, Martin SC, Herlea V, Fica S. Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup. Cancers 2022;14:4444. [DOI: 10.3390/cancers14184444] [Reference Citation Analysis]
|
| 19 |
Iorio J, Antonuzzo L, Scarpi E, D’amico M, Duranti C, Messerini L, Sparano C, Caputo D, Lavacchi D, Borzomati D, Antonelli A, Nibid L, Perrone G, Coppola A, Coppola R, di Costanzo F, Lastraioli E, Arcangeli A. Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas. IJMS 2022;23:10623. [DOI: 10.3390/ijms231810623] [Reference Citation Analysis]
|
| 20 |
Henker R, Lincke T, Hoffmeister A. Case report - Selective internal radiation therapy (SIRT) in a patient with hyperinsulinemic hypoglycemia due to a metastatic insulinoma with late onset of endocrine activity. Z Gastroenterol 2022;60:1332-4. [PMID: 35042268 DOI: 10.1055/a-1690-8018] [Reference Citation Analysis]
|
| 21 |
Pratap T, Jalal MJA, Jacob D, Mahadevan P, Nair SS, Raja S. Radiological Features of Zollinger–Ellison Syndrome: A Report of Two Cases. Indian J Radiol Imaging. [DOI: 10.1055/s-0042-1750725] [Reference Citation Analysis]
|
| 22 |
Khader A, Braschi-Amirfarzan M, McIntosh LJ, Gosangi B, Wortman JR, Wald C, Thomas R. Importance of tumor subtypes in cancer imaging. Eur J Radiol Open 2022;9:100433. [PMID: 35909389 DOI: 10.1016/j.ejro.2022.100433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Wang F, Yang Z, Chen X, Peng Y, Jiang H, Qin S. A novel diagnostic model for insulinoma. Discov Oncol 2022;13:68. [PMID: 35916979 DOI: 10.1007/s12672-022-00534-w] [Reference Citation Analysis]
|
| 24 |
Quan L, Liu Y, Cui W, Wang X, Zhang W, Wang Z, Guo C, Lu C, Hu F, Chen X. The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms. Lipids Health Dis 2022;21:58. [PMID: 35842659 DOI: 10.1186/s12944-022-01669-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Tanaka H, Minaga K, Otsuka Y, Masuta Y, Kamata K, Yamao K, Takenaka M, Hyodo T, Kimura M, Watanabe T, Kudo M. Pancreatic neuroendocrine carcinoma with unique morphological features mimicking intraductal papillary mucinous carcinoma: A case report. Front Med 2022;9. [DOI: 10.3389/fmed.2022.951834] [Reference Citation Analysis]
|
| 26 |
Ye J, Wu H, Li J, Liu C. Impact of Surgery on Non-Functional Pancreatic Neuroendocrine Tumors ≤2 cm: Analyses With Propensity Score–Based Inverse Probability of Treatment Weighting. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.890564] [Reference Citation Analysis]
|
| 27 |
Hasegawa S, Kobayashi N, Wild D, Kaul F, Okubo N, Suzuki A, Kurita Y, Takano S, Nakajima A, Ichikawa Y. Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. Cancers (Basel) 2022;14. [PMID: 35884377 DOI: 10.3390/cancers14143317] [Reference Citation Analysis]
|
| 28 |
Perinel J, Nappo G, Zerbi A, Heidsma CM, Nieveen van Dijkum EJM, Han HS, Yoon YS, Satoi S, Demir IE, Friess H, Vashist Y, Izbicki J, Muller AC, Gloor B, Sandini M, Gianotti L, Subtil F, Adham M. Sporadic nonfunctional pancreatic neuroendocrine tumors: Risk of lymph node metastases and aggressiveness according to tumor size: A multicenter international study. Surgery 2022:S0039-6060(22)00243-4. [PMID: 35623953 DOI: 10.1016/j.surg.2022.04.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 29 |
Li AY, Visser BC, Dua MM. Surgical Indications and Outcomes of Resection for Pancreatic Neuroendocrine Tumors with Vascular Involvement. Cancers 2022;14:2312. [DOI: 10.3390/cancers14092312] [Reference Citation Analysis]
|
| 30 |
Linn YL, Tan DMY, Cheow PC, Goh BKP. Unusual Case of Delayed Rupture of Pancreatic Neuroendocrine Tumor After Endoscopic Ultrasound and Biopsy. Pancreas 2022;51:e79-80. [PMID: 35973020 DOI: 10.1097/MPA.0000000000002042] [Reference Citation Analysis]
|
| 31 |
Una Cidon E. Vasoactive intestinal peptide secreting tumour: An overview. World J Gastrointest Oncol 2022; 14(4): 808-819 [DOI: 10.4251/wjgo.v14.i4.808] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 32 |
Kong W, Albers MB, Manoharan J, Goebel JN, Kann PH, Jesinghaus M, Bartsch DK. Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1. Cancers (Basel) 2022;14:1928. [PMID: 35454834 DOI: 10.3390/cancers14081928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 33 |
Simões de Carvalho F, Lima Ferreira J, Costa M, Tavares C, Marques AP. Clinical features of pheochromocytoma masked by VIP co-secretion. Endocrinología, Diabetes y Nutrición (English ed ) 2022;69:307-309. [DOI: 10.1016/j.endien.2022.05.001] [Reference Citation Analysis]
|
| 34 |
Oh D, Pyo J, Chung KH, Son BK. The Predicting Role of the Neutrophil-to-Lymphocyte Ratio for the Tumor Grade and Prognosis in Pancreatic Neuroendocrine Tumors. Diagnostics 2022;12:737. [DOI: 10.3390/diagnostics12030737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 35 |
Lee S, Maegawa FB, Joseph S, Alvarado LA, Mendoza-Ladd A, Elhanafi S, Philipovskiy A, Tyroch AH, Konstantinidis IT. Pancreatic Neuroendocrine Tumors: The Effect of Facility Type on Patient Survival. Pancreas 2022;51:282-7. [PMID: 35584387 DOI: 10.1097/MPA.0000000000002014] [Reference Citation Analysis]
|
| 36 |
Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 37 |
Han IW, Park J, Park EY, Yoon SJ, Jin G, Hwang DW, Jiang K, Kwon W, Xu X, Heo JS, Fu DL, Lee WJ, Bai X, Yoon YS, Yang YM, Ahn KS, Yuan C, Lee HK, Sun B, Park EK, Lee SE, Kang S, Lou W, Park SJ. Fate of Surgical Patients with Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An International Study Using Multi-Institutional Registries. Cancers (Basel) 2022;14:1038. [PMID: 35205787 DOI: 10.3390/cancers14041038] [Reference Citation Analysis]
|
| 38 |
Matli VVK, Wellman G, Jaganmohan S, Koticha K. Ampullary and Pancreatic Neuroendocrine Tumors: A Series of Cases and Review of the Literature. Cureus 2022. [DOI: 10.7759/cureus.21657] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 39 |
Mason D, Leimbach R, Kitz R, Vietor R, Vietor N. Calcitonin‐secreting pancreatic neuroendocrine tumor in a patient with elevated thyroid fine‐needle aspirate calcitonin washout: A case report and review of the literature. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5296] [Reference Citation Analysis]
|
| 40 |
Barthet M, Gasmi M, Gonzalez J. How to do EUS‐guided Radiofrequency Ablation of Pancreatic Neuroendocrine Tumors. Atlas of Endoscopic Ultrasonography 2022. [DOI: 10.1002/9781119522997.ch44] [Reference Citation Analysis]
|
| 41 |
Bodei L, Jayaprakasam VS, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors. Nuclear Oncology 2022. [DOI: 10.1007/978-3-031-05494-5_18] [Reference Citation Analysis]
|
| 42 |
Haslerud T. SPECT/CT in Neuroendrocrine Tumours. Clinical Applications of SPECT-CT 2022. [DOI: 10.1007/978-3-030-65850-2_6] [Reference Citation Analysis]
|
| 43 |
Bodei L, Jayaprakasam VS, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_18-2] [Reference Citation Analysis]
|
| 44 |
Foong A, Buxbaum J. Diagnosis and Management of Pancreatic Neuroendocrine Tumors and Other Rare Pancreatic Neoplasms. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_43] [Reference Citation Analysis]
|
| 45 |
Gonzalez C, Desantis A, Read M, Karachristos A. Surgical Management of Pancreatic Neuroendocrine Tumors (PNET). Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_40] [Reference Citation Analysis]
|
| 46 |
Keihanian T, Othman M. Epidemiology, Pathogenesis, and Prognosis of Pancreatic Neuroendocrine Tumors. Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_36] [Reference Citation Analysis]
|
| 47 |
Shi H, Chen H, Qian B, Huang Z, Tan P, Peng Y, Tang X, Ye M. The 100 most cited articles on pancreatic neuroendocrine tumors from 2000 to 2020: a bibliometric analysis. Jpn J Clin Oncol 2021:hyab205. [PMID: 34954797 DOI: 10.1093/jjco/hyab205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 48 |
Weerasuriya S, Palmer K, Gregory S, Whitelaw BC, Gonzalez E, Srirajaskanthan R. Mesenteric Variceal Haemorrhage and Ectopic Cushing's Syndrome as Presenting Features of a Pancreatic Neuroendocrine Tumour Recurrence. Case Rep Gastroenterol 2021;15:919-26. [PMID: 34899150 DOI: 10.1159/000518021] [Reference Citation Analysis]
|
| 49 |
Vivanet G, Gervaso L, Laffi A, Rubino M, Spada F, Fazio N. Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile. Expert Opin Drug Saf 2021;:1-8. [PMID: 34724869 DOI: 10.1080/14740338.2022.2000964] [Reference Citation Analysis]
|
| 50 |
Bhattacharya S, Blau JE, Cochran C, Auh S, Weinstein LS, Jensen RT, Wank S. Validity of Secretin Stimulation Testing on Proton Pump Inhibitor Therapy for Diagnosis of Zollinger-Ellison Syndrome. Am J Gastroenterol 2021;116:2216-21. [PMID: 34515664 DOI: 10.14309/ajg.0000000000001487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 51 |
Shi M, Fan Z, Xu J, Yang J, Li Y, Gao C, Su P, Wang X, Zhan H. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs. Biochim Biophys Acta Rev Cancer 2021;1876:188637. [PMID: 34678439 DOI: 10.1016/j.bbcan.2021.188637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 52 |
Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]
|
| 53 |
Srirajaskanthan R, Pavel M, Kulke M, Clement D, Houchard A, Keeber L, Weickert MO. Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST. Clin Ther 2021;43:1779-85. [PMID: 34598813 DOI: 10.1016/j.clinthera.2021.08.014] [Reference Citation Analysis]
|
| 54 |
Rossi RE, Elvevi A, Citterio D, Coppa J, Invernizzi P, Mazzaferro V, Massironi S. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World J Gastroenterol 2021; 27(35): 5890-5907 [PMID: 34629807 DOI: 10.3748/wjg.v27.i35.5890] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 55 |
Starr J, Puebla G, McMillan J, Lewis JT, Kasi PM. Microsatellite Instability-High, Malignant Insulinoma With Brain Metastasis. Cureus 2021;13:e16969. [PMID: 34527457 DOI: 10.7759/cureus.16969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 56 |
Danti G, Flammia F, Matteuzzi B, Cozzi D, Berti V, Grazzini G, Pradella S, Recchia L, Brunese L, Miele V. Gastrointestinal neuroendocrine neoplasms (GI-NENs): hot topics in morphological, functional, and prognostic imaging. Radiol Med 2021;126:1497-507. [PMID: 34427861 DOI: 10.1007/s11547-021-01408-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 57 |
Vaghaiwalla T, Keutgen XM. Surgical Management of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:243-52. [PMID: 32151358 DOI: 10.1016/j.soc.2019.11.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 58 |
Barthet M, Giovannini M, Gasmi M, Lesavre N, Boustière C, Napoleon B, LaQuiere A, Koch S, Vanbiervliet G, Gonzalez JM. Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms. Endosc Int Open 2021;9:E1178-85. [PMID: 34447860 DOI: 10.1055/a-1479-2199] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 59 |
Mastoraki A, Schizas D, Papoutsi E, Ntella V, Kanavidis P, Sioulas A, Tsoli M, Charalampopoulos G, Vailas M, Felekouras E. Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas. In Vivo 2020;34:3573-82. [PMID: 33144470 DOI: 10.21873/invivo.12201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 60 |
Melita G, Pallio S, Tortora A, Crinò SF, Macrì A, Dionigi G. Diagnostic and Interventional Role of Endoscopic Ultrasonography for the Management of Pancreatic Neuroendocrine Neoplasms. J Clin Med 2021;10:2638. [PMID: 34203922 DOI: 10.3390/jcm10122638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 61 |
Simões de Carvalho F, Lima Ferreira J, Costa M, Tavares C, Marques AP. Clinical features of pheochromocytoma masked by VIP co-secretion. Endocrinol Diabetes Nutr 2021:S2530-0164(21)00113-0. [PMID: 34127441 DOI: 10.1016/j.endinu.2021.02.003] [Reference Citation Analysis]
|
| 62 |
Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 63 |
Guccione L, Gough K, Drosdowsky A, Price T, Pavlakis N, Wyld D, Ransom D, Michael M, Schofield P. The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. Patient Educ Couns 2021:S0738-3991(21)00335-9. [PMID: 34030927 DOI: 10.1016/j.pec.2021.05.006] [Reference Citation Analysis]
|
| 64 |
Zafar M, Muhammad T, Saher NU, Toqeer M. Hypertrophic Gastric folds with Hypomagnesemia, linking the dots. Pak J Med Sci 2021;37:1237-40. [PMID: 34290814 DOI: 10.12669/pjms.37.4.3984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 65 |
Tong Z, Wang L, Shi W, Zeng Y, Zhang H, Liu L, Zheng Y, Chen C, Xia W, Fang W, Zhao P. Clonal Evolution Dynamics in Primary and Metastatic Lesions of Pancreatic Neuroendocrine Neoplasms. Front Med (Lausanne) 2021;8:620988. [PMID: 34026777 DOI: 10.3389/fmed.2021.620988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 66 |
Mowrey K, Northrup H, Rougeau P, Hashmi SS, Krueger DA, Ebrahimi-Fakhari D, Towbin AJ, Trout AT, Capal JK, Franz DN, Rodriguez-Buritica D. Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports. Front Neurol 2021;12:627672. [PMID: 33897589 DOI: 10.3389/fneur.2021.627672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 67 |
Miura T, Ohtsuka H, Aoki T, Aoki S, Hata T, Takadate T, Maeda S, Ariake K, Kawaguchi K, Masuda K, Ishida M, Mizuma M, Nakagawa K, Morikawa T, Fujishima F, Kamei T, Sasano H, Unno M. Increased neutrophil-lymphocyte ratio predicts recurrence in patients with well-differentiated pancreatic neuroendocrine neoplasm based on the 2017 World Health Organization classification. BMC Surg 2021;21:176. [PMID: 33789657 DOI: 10.1186/s12893-021-01178-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 68 |
Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021;13:231-55. [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Reference Citation Analysis]
|
| 69 |
Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021;13:231-55. [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 70 |
Sánchez-salazar SM, Torres-alzate S, Muñoz-cortés VM, Builes-barrera CA, Gutiérrez-montoya JI, Román-gonzález A. VIPoma: a rare cause of diarrhea. A case report. Rev Fac Med 2021;69. [DOI: 10.15446/revfacmed.v69n3.81603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 71 |
Kumar S, Raobiakady R, Watkins D, Terlizzo M, Bhogal RH. Radical resection of large metastatic non-functioning pancreatic neuroendocrine carcinoma complicated by splenic vein thrombosis and sinistral portal hypertension. Int J Surg Case Rep 2021;81:105724. [PMID: 33820735 DOI: 10.1016/j.ijscr.2021.105724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 72 |
Wu W, Chen J, Bai C, Chi Y, Du Y, Feng S, Huo L, Jiang Y, Li J, Lou W, Luo J, Shao C, Shen L, Wang F, Wang L, Wang O, Wang Y, Wu H, Xing X, Xu J, Xue H, Xue L, Yang Y, Yu X, Yuan C, Zhao H, Zhu X, Zhao Y. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). Journal of Pancreatology 2021;4:1-17. [DOI: 10.1097/jp9.0000000000000064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 73 |
Park A, Martin A, Carlos R, Neychev V. Primary versus secondary nature of mesenteric neuroendocrine tumours. BMJ Case Rep 2021;14. [PMID: 33541996 DOI: 10.1136/bcr-2020-239217] [Reference Citation Analysis]
|
| 74 |
Sung MJ, Chung MJ. Current Paradigm of Treatment for Pancreatic Neuroendocrine Tumor. Korean J Pancreas Biliary Tract 2021;26:24-32. [DOI: 10.15279/kpba.2021.26.1.24] [Reference Citation Analysis]
|
| 75 |
Keihanian T, Othman M. Epidemiology, Pathogenesis, and Prognosis of Pancreatic Neuroendocrine Tumors. Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_36-1] [Reference Citation Analysis]
|
| 76 |
Ito T, Masui T, Komoto I, Doi R, Osamura RY, Sakurai A, Ikeda M, Takano K, Igarashi H, Shimatsu A, Nakamura K, Nakamoto Y, Hijioka S, Morita K, Ishikawa Y, Ohike N, Kasajima A, Kushima R, Kojima M, Sasano H, Hirano S, Mizuno N, Aoki T, Aoki T, Ohtsuka T, Okumura T, Kimura Y, Kudo A, Konishi T, Matsumoto I, Kobayashi N, Fujimori N, Honma Y, Morizane C, Uchino S, Horiuchi K, Yamasaki M, Matsubayashi J, Sato Y, Sekiguchi M, Abe S, Okusaka T, Kida M, Kimura W, Tanaka M, Majima Y, Jensen RT, Hirata K, Imamura M, Uemoto S. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. J Gastroenterol 2021;56:1033-44. [PMID: 34586495 DOI: 10.1007/s00535-021-01827-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 77 |
Muniraj T, Aslanian HR. Pancreatic Neuroendocrine Tumors. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_81] [Reference Citation Analysis]
|
| 78 |
Zhao Y, Wang D, Xia W, Chen W, Liu Z. Internal medicine treatment of pancreatic lesions. Integrative Pancreatic Intervention Therapy 2021. [DOI: 10.1016/b978-0-12-819402-7.00004-8] [Reference Citation Analysis]
|
| 79 |
Gonzalez C, Desantis A, Read M, Karachristos A. Surgical Management of Pancreatic Neuroendocrine Tumors (PNET). Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_40-1] [Reference Citation Analysis]
|
| 80 |
Viúdez A, Crespo G, Gómez Dorronsoro ML, Arozarena I, Marín-Méndez JJ, Custodio A, Benavent M, Goñi S, García-Paredes B, Hernando J, Durantez M, Alonso V, Riesco MDC, López C, Jiménez-Fonseca P, San Vicente BL, González-Borja I, Sevilla I, Hernández-Garcia I, Carmona-Bayonas A, Capdevila J, Pérez-Sanz J, García-Carbonero R, Pérez-Ricarte L, Llanos M, Vera R, De Jesús Acosta A. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. Pancreatology 2021;21:215-23. [PMID: 33358592 DOI: 10.1016/j.pan.2020.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 81 |
Sukrithan V, Konda B. Epidemiology and Diagnosis of Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_1] [Reference Citation Analysis]
|
| 82 |
Foong A, Buxbaum J. Diagnosis and Management of Pancreatic Neuroendocrine Tumors and Other Rare Pancreatic Neoplasms. Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_43-1] [Reference Citation Analysis]
|
| 83 |
Liu X, Chin W, Pan C, Zhang W, Yu J, Zheng S, Liu Y. Risk of malignancy and prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors. Gland Surg 2021;10:219-32. [PMID: 33633978 DOI: 10.21037/gs-20-582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 84 |
Whitt J, Hong WS, Telange RR, Lin CP, Bibb J, Beebe DJ, Chen H, Jaskula-Sztul R. Non-toxic fragment of botulinum neurotoxin type A and monomethyl auristatin E conjugate for targeted therapy for neuroendocrine tumors. Cancer Gene Ther 2020;27:898-909. [PMID: 32029905 DOI: 10.1038/s41417-020-0167-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 85 |
Titan AL, Norton JA, Fisher AT, Foster DS, Harris EJ, Worhunsky DJ, Worth PJ, Dua MM, Visser BC, Poultsides GA, Longaker MT, Jensen RT. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors. JAMA Netw Open 2020;3:e2024318. [PMID: 33146734 DOI: 10.1001/jamanetworkopen.2020.24318] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 86 |
Patel AV, Shah DN, Godbole A, Shah TA, Patel SV. A SYNCHRONOUS INCIDENCE OF ASYMPTOMATIC JEJUNAL GIST IN PATIENT WITH NON- FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOR (PNET). ijsr 2020. [DOI: 10.36106/ijsr/2901968] [Reference Citation Analysis]
|
| 87 |
Nosé BD, Ottmann SE, Lauria AL, Hawksworth JS. Synchronous Hemihepatectomy With Pancreatectomy Through Application of Associated Liver Partition and Portal Vein Ligation for a Metastatic Gastrinoma. Am Surg 2020;:3134820951493. [PMID: 33125283 DOI: 10.1177/0003134820951493] [Reference Citation Analysis]
|
| 88 |
Zhang WH, Wang WQ, Han X, Gao HL, Xu SS, Li S, Li TJ, Xu HX, Li H, Ye LY, Lin X, Wu CT, Long J, Yu XJ, Liu L. Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors. J Immunother Cancer 2020;8:e001188. [PMID: 33055204 DOI: 10.1136/jitc-2020-001188] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 89 |
Kojima M, Sudo T, Kubota H, Hadano N, Shimizu W, Suzuki T, Ishiyama K, Onoe T, Shimizu Y, Tashiro H. A Case of Intraperitoneal Hemorrhage Due to Rupture of Liver Metastases from a Pancreatic Neuroendocrine Tumor and Long-Term Survival through Multidisciplinary Treatment. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2020;53:784-791. [DOI: 10.5833/jjgs.2019.0079] [Reference Citation Analysis]
|
| 90 |
Wang WZ, Xu LJ, Hu DM, Tang W. Case of an abnormal procalcitonin-producing metastatic pancreatic neuroendocrine tumor. Clin Case Rep 2020;8:2269-72. [PMID: 33235774 DOI: 10.1002/ccr3.3187] [Reference Citation Analysis]
|
| 91 |
Nelakurti DD, Pappula AL, Rajasekaran S, Miles WO, Petreaca RC. Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer. Cancers (Basel) 2020;12:E2616. [PMID: 32937789 DOI: 10.3390/cancers12092616] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 92 |
Worth PJ, Leal J, Ding Q, Trickey A, Dua MM, Chatzizacharias N, Soonawalla Z, Athanasopoulos P, Toumpanakis C, Hansen P, Parks RW, Connor S, Parker K, Koea J, Srinavasa S, Ielpo B, Vicente Lopez E, Lawrence B, Visser BC; International Pancreatic Neuroendocrine Tumor Study Group. Pancreatic grade 3 neuroendocrine tumors behave similarly to neuroendocrine carcinomas following resection: a multi-center, international appraisal of the WHO 2010 and WHO 2017 staging schema for pancreatic neuroendocrine lesions. HPB (Oxford) 2020;22:1359-67. [PMID: 32081540 DOI: 10.1016/j.hpb.2019.12.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 93 |
Khalil A, Ewald J, Marchese U, Autret A, Garnier J, Niccoli P, Piana G, Poizat F, Giovannini M, Delpero JR, Turrini O. A single-center experience with pancreatic cystic neuroendocrine tumors. World J Surg Oncol 2020;18:208. [PMID: 32799893 DOI: 10.1186/s12957-020-01994-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 94 |
Milanetto AC, Pacciani S, Fassan M, Pasquali C. Pancreatic Neuroendocrine Neoplasms and Gastrointestinal Stromal Tumors: A Single-Institution Experience of a Rare Association and Review of the Literature. Pancreas 2020;49:918-23. [PMID: 32658075 DOI: 10.1097/MPA.0000000000001599] [Reference Citation Analysis]
|
| 95 |
Fathi AH, Romanyshyn J, Barati M, Choudhury U, Chen A, Sosa JA. Predicting Aggressive Behavior in Nonfunctional Pancreatic Neuroendocrine Tumors With Emphasis on Tumor Size Significance and Survival Trends: A Population-Based Analysis of 1787 Patients. Am Surg 2020;86:458-66. [PMID: 32684030 DOI: 10.1177/0003134820919730] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 96 |
Patel K, Siraj S, Smith C, Nair M, Vishwanatha JK, Basha R. Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy. Crit Rev Oncog 2019;24:105-18. [PMID: 31679206 DOI: 10.1615/CritRevOncog.2019031417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 97 |
Johnston ME 2nd, Carter MM, Wilson GC, Ahmad SA, Patel SH. Surgical management of primary pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:578-89. [PMID: 32655937 DOI: 10.21037/jgo.2019.12.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 98 |
Davila A, Menias CO, Alhalabi K, Lall C, Pickhardt PJ, Lubner M, Elsayes KM. Multiple Endocrine Neoplasia: Spectrum of Abdominal Manifestations. AJR Am J Roentgenol 2020;215:885-95. [PMID: 32755185 DOI: 10.2214/AJR.19.22542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 99 |
Fukami Y, Saito T, Arikawa T, Osawa T, Komatsu S, Kaneko K, Suzuki K, Takahashi E, Tsuzuki T, Sano T. Inferior pancreaticoduodenal artery pseudoaneurysm rupture caused by the pancreatic neuroendocrine tumor. Surgery 2020;168:e1-e2. [DOI: 10.1016/j.surg.2020.02.019] [Reference Citation Analysis]
|
| 100 |
Zhang WH, Wang WQ, Gao HL, Xu SS, Li S, Li TJ, Han X, Xu HX, Li H, Jiang W, Ye LY, Lin X, Wu CT, Yu XJ, Liu L. Tumor-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumor. J Clin Endocrinol Metab 2020;105:dgaa196. [PMID: 32285127 DOI: 10.1210/clinem/dgaa196] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 101 |
Tan QQ, Wang X, Yang L, Chen YH, Tan CL, Zhu XM, Ke NW, Liu XB. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors. Medicine (Baltimore) 2020;99:e20324. [PMID: 32541455 DOI: 10.1097/MD.0000000000020324] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 102 |
Souche R, Coignac A, Dupuy M, Bertrand M, Raingeart I, Guiu B, Herrero A, Panaro F, Obled S, Portales F, Riviere B, Ramos J, Borie F, Quenet F, Colombo PE, Prudhomme M, Assenat E, Fabre JM; Renaten Languedoc-Roussillon Study Group, Réseau de référence clinique pour les tumeurs endocrines malignes sporadiques et héréditaires. Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients. Clin Res Hepatol Gastroenterol 2020;44:286-94. [PMID: 31543336 DOI: 10.1016/j.clinre.2019.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 103 |
Dong DH, Zhang XF, Lopez-Aguiar AG, Poultsides G, Rocha F, Weber S, Fields R, Idrees K, Cho C, Spolverato G, Maithel SK, Pawlik TM. Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. J Surg Oncol 2020;122:442-9. [PMID: 32470159 DOI: 10.1002/jso.25978] [Reference Citation Analysis]
|
| 104 |
Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 105 |
Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol 2020; 26(19): 2305-2322 [PMID: 32476795 DOI: 10.3748/wjg.v26.i19.2305] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 16.7] [Reference Citation Analysis]
|
| 106 |
Lopez-Aguiar AG, Postlewait LM, Ethun CG, Zaidi MY, Zhelnin K, Krasinskas A, Russell MC, Kooby DA, Cardona K, El-Rayes BF, Maithel SK. STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target? J Gastrointest Surg 2020;24:1138-48. [PMID: 31144189 DOI: 10.1007/s11605-019-04261-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 107 |
Isyangulova AZ, Khasanov RS, Enikeev RF. Targeted therapy for gastrointestinal and pancreatic neuroendocrine tumors. Malignant Tumours 2020;9:49-58. [DOI: 10.18027/2224-5057-2019-9-4-49-58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 108 |
Younan G. Pancreas Solid Tumors. Surg Clin North Am 2020;100:565-80. [PMID: 32402301 DOI: 10.1016/j.suc.2020.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 109 |
Han X, Chen W, Chen P, Zhou W, Rong Y, Lv Y, Li JA, Ji Y, Chen W, Lou W, Xu X. Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:514-23. [PMID: 32282764 DOI: 10.1097/MPA.0000000000001535] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 110 |
Noda S, Chikazawa K, Suzuki Y, Imaizumi Y, Yamamura H. Involvement of the γ1 subunit of the large-conductance Ca2+-activated K+ channel in the proliferation of human somatostatinoma cells. Biochem Biophys Res Commun 2020;525:1032-7. [PMID: 32178873 DOI: 10.1016/j.bbrc.2020.02.176] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 111 |
Iglesias-Garcia J, de la Iglesia-Garcia D, Olmos-Martinez JM, Lariño-Noia J, Dominguez-Muñoz JE. Differential diagnosis of solid pancreatic masses. Minerva Gastroenterol Dietol 2020;66:70-81. [PMID: 31994370 DOI: 10.23736/S1121-421X.20.02646-X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 112 |
Temraz S, Haidar M, Assi R, Hakim A, Jabra E, Charafeddine M, Halabi IE, Mukherji D, Shamseddine A. Pancreatic Neuroendocrine Tumors: Experience of a Tertiary Care Center in Lebanon. Ann Cancer Res Therap 2020;28:9-15. [DOI: 10.4993/acrt.28.9] [Reference Citation Analysis]
|
| 113 |
Landoni L, Marchegiani G, Pollini T, Cingarlini S, D'Onofrio M, Capelli P, De Robertis R, Davì MV, Amodio A, Impellizzeri H, Malpaga A, Miotto M, Boninsegna L, Crepaz L, Nessi C, Zingaretti CC, Paiella S, Esposito A, Casetti L, Malleo G, Tuveri M, Butturini G, Salvia R, Scarpa A, Falconi M, Bassi C. The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-trend and Outcome Analysis From 587 Consecutive Resections at a High-volume Institution. Ann Surg 2019;269:725-32. [PMID: 29189384 DOI: 10.1097/SLA.0000000000002594] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 114 |
Concors SJ, Sinnamon AJ, Ecker BL, Metz DC, Vollmer CM, Fraker DL, Roses RE. The impact of surgery for metastatic pancreatic neuroendocrine tumor: a contemporary evaluation matching for chromogranin a level. HPB (Oxford) 2020;22:83-90. [PMID: 31239188 DOI: 10.1016/j.hpb.2019.05.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 115 |
Rozenblum L, Mokrane F, Yeh R, Sinigaglia M, Besson FL, Seban R, Zadro C, Dierickx L, Chougnet CN, Partouche E, Revel-mouroz P, Zhao B, Otal P, Schwartz LH, Dercle L. Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach. European Journal of Radiology 2020;122:108743. [DOI: 10.1016/j.ejrad.2019.108743] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 116 |
Muniraj T, Aslanian HR. Pancreatic Neuroendocrine Tumors. Geriatric Gastroenterology 2020. [DOI: 10.1007/978-3-319-90761-1_81-1] [Reference Citation Analysis]
|
| 117 |
Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Critical Reviews in Oncology/Hematology 2020;145:102835. [DOI: 10.1016/j.critrevonc.2019.102835] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 118 |
Rehfeld JF. Premises for Cholecystokinin and Gastrin Peptides in Diabetes Therapy. Clin Med Insights Endocrinol Diabetes 2019;12:1179551419883608. [PMID: 31853211 DOI: 10.1177/1179551419883608] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 119 |
Guccione L, Gough K, Drosdowsky A, Fisher K, Price T, Pavlakis N, Khasraw M, Wyld D, Ransom D, Kong G, Rogers M, Leyden S, Leyden J, Michael M, Schofield P. Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR Res Protoc 2019;8:e14361. [PMID: 31793892 DOI: 10.2196/14361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 120 |
Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 121 |
Hauser H, Gerson DS, Reidy-Lagunes D, Raj N. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors. Curr Treat Options Oncol. 2019;20:87. [PMID: 31776785 DOI: 10.1007/s11864-019-0690-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 122 |
Ren B, Rose JB, Liu Y, Jaskular-Sztul R, Contreras C, Beck A, Chen H. Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors. J Clin Med 2019;8:E1980. [PMID: 31739580 DOI: 10.3390/jcm8111980] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 123 |
Dave A, Beal EW, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha FG, Kanji Z, Ronnekleiv-Kelly S, Rendell VR, Fields RC, Krasnick BA, Idrees K, Smith PM, Nathan H, Beems M, Maithel SK, Pawlik TM, Schmidt CR, Dillhoff ME. Evaluating the ACS NSQIP Risk Calculator in Primary Pancreatic Neuroendocrine Tumor: Results from the US Neuroendocrine Tumor Study Group. J Gastrointest Surg 2019;23:2225-31. [PMID: 30941685 DOI: 10.1007/s11605-019-04120-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 124 |
Eusebi LH, Thorburn D, Toumpanakis C, Frazzoni L, Johnson G, Vessal S, Luong TV, Caplin M, Pereira SP. Endoscopic ultrasound-guided fine-needle aspiration vs fine-needle biopsy for the diagnosis of pancreatic neuroendocrine tumors. Endosc Int Open 2019;7:E1393-9. [PMID: 31673610 DOI: 10.1055/a-0967-4684] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 125 |
Moore PC, Qi JY, Thamsen M, Ghosh R, Peng J, Gliedt MJ, Meza-Acevedo R, Warren RE, Hiniker A, Kim GE, Maly DJ, Backes BJ, Papa FR, Oakes SA. Parallel Signaling through IRE1α and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival. Cancer Res 2019;79:6190-203. [PMID: 31672843 DOI: 10.1158/0008-5472.CAN-19-1116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 126 |
Liu Y, Ye S, Zhu Y, He X, Pan J, Chen S, Ye B, Wang L. Impact of tumour size on metastasis and survival in patients with pancreatic neuroendocrine tumours (PNETs): A population based study. J Cancer 2019;10:6349-57. [PMID: 31772667 DOI: 10.7150/jca.27779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 127 |
Sureka B, Varshney V, Elhence P, Bharti J, Yadav T, Garg PK, Khera PS. Unusual Case of a Pancreatic Neuroendocrine Tumor Containing a Central Scar. ACG Case Rep J 2019;6:1-5. [PMID: 31620494 DOI: 10.14309/crj.0000000000000047] [Reference Citation Analysis]
|
| 128 |
Gamboa AC, Liu Y, Lee RM, Zaidi MY, Staley CA, Kooby DA, Winer JH, Shah MM, Russell MC, Cardona K, Maithel SK. Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel? J Surg Oncol 2019;120:1293-301. [PMID: 31621090 DOI: 10.1002/jso.25731] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 129 |
Siddappa PK, Vege SS. Vasoactive Intestinal Peptide-Secreting Tumors: A Review. Pancreas 2019;48:1119-25. [PMID: 31609932 DOI: 10.1097/MPA.0000000000001402] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 130 |
Leeds JS, Nayar MK, Bekkali NLH, Wilson CH, Johnson SJ, Haugk B, Darne A, Oppong KW. Endoscopic ultrasound-guided fine-needle biopsy is superior to fine-needle aspiration in assessing pancreatic neuroendocrine tumors. Endosc Int Open 2019;7:E1281-7. [PMID: 31579710 DOI: 10.1055/a-0990-9611] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 131 |
Dong D, Zhang X, Poultsides G, Rocha F, Weber S, Fields R, Idrees K, Cho C, Maithel SK, Pawlik TM; other members of the US Neuroendocrine Tumor Study Group. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi‐institutional study of 392 cases. J Surg Oncol 2019;120:1071-9. [DOI: 10.1002/jso.25716] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 132 |
Abdullayeva L. VIPoma: Mechanisms, clinical presentation, diagnosis and treatment (Review). Wrld Acd Sci 2019. [DOI: 10.3892/wasj.2019.22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 133 |
Zaidi MY, Lopez-Aguiar AG, Switchenko JM, Lipscomb J, Andreasi V, Partelli S, Gamboa AC, Lee RM, Poultsides GA, Dillhoff M, Rocha FG, Idrees K, Cho CS, Weber SM, Fields RC, Staley CA 3rd, Falconi M, Maithel SK. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. Ann Surg 2019;270:422-33. [PMID: 31283562 DOI: 10.1097/SLA.0000000000003461] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 134 |
Wiens E, Kovaltchouk U, Koomson A, Targownik LE. The Clinician's Guide to Proton-Pump Inhibitor Discontinuation. J Clin Gastroenterol 2019;53:553-9. [PMID: 31356559 DOI: 10.1097/MCG.0000000000001243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 135 |
Egorov AV, Lezhinskiy DV, Vasilyev IA, Musaev GK, Parnova VA. [Choice of surgical approach to insulin-producing pancreatic tumors]. Khirurgiia (Mosk) 2019;:41-5. [PMID: 31464273 DOI: 10.17116/hirurgia201908141] [Reference Citation Analysis]
|
| 136 |
Shao QQ, Zhao BB, Dong LB, Cao HT, Wang WB. Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies. World J Gastroenterol 2019; 25(32): 4673-4681 [PMID: 31528093 DOI: 10.3748/wjg.v25.i32.4673] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 137 |
Braga TL, Pinto SR, dos Reis SRR, Portilho FL, da Silva de Barros AO, Bernardes ES, dos Santos SN, Alencar LMR, Ricci-junior E, Santos-oliveira R. Octreotide Nanoparticles Showed Affinity for In Vivo MIA Paca-2 Inducted Pancreas Ductal Adenocarcinoma Mimicking Pancreatic Polypeptide-Secreting Tumor of the Distal Pancreas (PPoma). Pharm Res 2019;36. [DOI: 10.1007/s11095-019-2678-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 138 |
Partelli S, Mazza M, Andreasi V, Muffatti F, Crippa S, Tamburrino D, Falconi M. Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. Surgery 2019;166:157-63. [DOI: 10.1016/j.surg.2019.04.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 139 |
Maggio I, Mollica V, Brighi N, Lamberti G, Manuzzi L, Ricci AD, Campana D. The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest 2020;43:139-48. [DOI: 10.1007/s40618-019-01091-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 140 |
Gao L, Natov NS, Daly KP, Masud F, Chaudhry S, Sterling MJ, Saif MW. An update on the management of pancreatic neuroendocrine tumors. Anticancer Drugs. 2018;29:597-612. [PMID: 29782352 DOI: 10.1097/cad.0000000000000633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 141 |
Zamir MA, Hakim W, Yusuf S, Thomas R. Imaging of Pancreatic-Neuroendocrine Tumours: An Outline of Conventional Radiological Techniques. CRP 2019;12:135-55. [DOI: 10.2174/1874471012666190214165845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 142 |
Cui Y, Khanna LG, Saqi A, Crapanzano JP, Mitchell JM, Sethi A, Gonda TA, Kluger MD, Schrope BA, Allendorf J, Chabot JA, Poneros JM. The Role of Endoscopic Ultrasound-Guided Ki67 in the Management of Non-Functioning Pancreatic Neuroendocrine Tumors. Clin Endosc 2020;53:213-20. [PMID: 31302988 DOI: 10.5946/ce.2019.068] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 143 |
Dai H, Chen H, Hong X, Han X, Xu Q, Pang H, Yuan J, Wang X, Xu P, Jiang J, Jiang R, Zhuang Z, Zhao Y, Wu W. Early detection of cognitive impairment in patients with insulinoma. Endocrine 2019;65:524-30. [PMID: 31292840 DOI: 10.1007/s12020-019-01994-x] [Reference Citation Analysis]
|
| 144 |
Gharios J, Hain E, Dohan A, Prat F, Terris B, Bertherat J, Coriat R, Dousset B, Gaujoux S. Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas. Best Pract Res Clin Endocrinol Metab. 2019;33:101294. [PMID: 31351817 DOI: 10.1016/j.beem.2019.101294] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 145 |
Rozenblum L, Mokrane FZ, Yeh R, Sinigaglia M, Besson F, Seban RD, Chougnet CN, Revel-Mouroz P, Zhao B, Otal P, Schwartz LH, Dercle L. The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI. Abdom Radiol (NY) 2019;44:2474-93. [PMID: 30980115 DOI: 10.1007/s00261-019-01994-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 146 |
Lopez-aguiar AG, Ethun CG, Zaidi MY, Rocha FG, Poultsides GA, Dillhoff M, Fields RC, Idrees K, Cho CS, Abbott DE, Cardona K, Maithel SK. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management. Surgery 2019;166:15-21. [DOI: 10.1016/j.surg.2019.03.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 147 |
Schimmack S, Yang Y, Felix K, Herbst M, Li Y, Schenk M, Bergmann F, Hackert T, Strobel O. C-reactive protein (CRP) promotes malignant properties in pancreatic neuroendocrine neoplasms. Endocr Connect 2019;8:1007-19. [PMID: 31234146 DOI: 10.1530/EC-19-0132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 148 |
Cejas P, Drier Y, Dreijerink KMA, Brosens LAA, Deshpande V, Epstein CB, Conemans EB, Morsink FHM, Graham MK, Valk GD, Vriens MR, Castillo CF, Ferrone CR, Adar T, Bowden M, Whitton HJ, Da Silva A, Font-Tello A, Long HW, Gaskell E, Shoresh N, Heaphy CM, Sicinska E, Kulke MH, Chung DC, Bernstein BE, Shivdasani RA. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nat Med 2019;25:1260-5. [PMID: 31263286 DOI: 10.1038/s41591-019-0493-4] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 21.5] [Reference Citation Analysis]
|
| 149 |
Ito T, Tori M, Hashigaki S, Kimura N, Sato K, Ohki E, Sawaki A, Okusaka T. Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study. Jpn J Clin Oncol 2019;49:354-60. [PMID: 30834940 DOI: 10.1093/jjco/hyz009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 150 |
Barthet M. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumor. Ann Endocrinol (Paris) 2019;80:182-4. [PMID: 31053252 DOI: 10.1016/j.ando.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 151 |
Lopez-Aguiar AG, Zaidi MY, Beal EW, Dillhoff M, Cannon JGD, Poultsides GA, Kanji ZS, Rocha FG, Marincola Smith P, Idrees K, Beems M, Cho CS, Fisher AV, Weber SM, Krasnick BA, Fields RC, Cardona K, Maithel SK. Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. Ann Surg Oncol. 2019;26:2517-2524. [PMID: 31004295 DOI: 10.1245/s10434-019-07367-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 152 |
Kozlov IA, Baydarova MD. Duodenum-sparing pancreatic head resections for benign tumors and chronic pancreatitis. Ann hir gepatol 2019;24:92-8. [DOI: 10.16931/1995-5464.2019192-98] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 153 |
Ratnayake CBB, Loveday BP, Windsor JA, Lawrence B, Pandanaboyana S. Patient characteristics and clinical outcomes following initial surgical intervention for MEN1 associated pancreatic neuroendocrine tumours: A systematic review and exploratory meta-analysis of the literature. Pancreatology 2019;19:462-71. [PMID: 30894303 DOI: 10.1016/j.pan.2019.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 154 |
Cornacchia C, Rutigliani M, Serventi A, Ciferri E, Angelini G, Filauro M. Pancreatic Ductal Adenocarcinoma Derived From an Intraductal Papillary Neoplasm With Synchronous Incidental Glucagonoma: A Case Report and Literature Review. Pancreas 2019;48:e24-6. [PMID: 30973467 DOI: 10.1097/MPA.0000000000001282] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 155 |
Guilmette J, Nosé V. Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms. Semin Diagn Pathol 2019;36:229-39. [PMID: 30910348 DOI: 10.1053/j.semdp.2019.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 156 |
Norton JA, Foster DS, Ito T, Jensen RT. Gastrinomas: Medical or Surgical Treatment. Endocrinol Metab Clin North Am. 2018;47:577-601. [PMID: 30098717 DOI: 10.1016/j.ecl.2018.04.009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 157 |
Herrera-Martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocr Relat Cancer 2019;26:R157-79. [PMID: 30615596 DOI: 10.1530/ERC-18-0354] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 158 |
Yohanathan L, Dossa F, St Germain AT, Golbafian F, Moulton CA, McGilvray ID, Greig PD, Serra S, Wei AC, Jhaveri KS, Gallinger S, Cleary SP. Management and surveillance of non-functional pancreatic neuroendocrine tumours: Retrospective review. Pancreatology 2019;19:360-6. [PMID: 30803874 DOI: 10.1016/j.pan.2019.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 159 |
Cai L, Michelakos T, Deshpande V, Arora KS, Yamada T, Ting DT, Taylor MS, Castillo CF, Warshaw AL, Lillemoe KD, Ferrone S, Ferrone CR. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). Clin Cancer Res 2019;25:2644-55. [PMID: 30670493 DOI: 10.1158/1078-0432.CCR-18-1401] [Cited by in Crossref: 23] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 160 |
Moore PC, Qi JY, Thamsen M, Ghosh R, Peng J, Gliedt MJ, Meza-acevedo R, Warren RE, Hiniker A, Kim GE, Maly DJ, Backes BJ, Papa FR, Oakes SA. Parallel signaling through IRE1α and PERK regulates pancreatic neuroendocrine tumor growth and survival.. [DOI: 10.1101/522102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 161 |
Thavaraputta S, Graham S, Rivas Mejia AM, Lado-Abeal J. Duodenal somatostatinoma presenting as obstructive jaundice with the coexistence of a gastrointestinal stromal tumour in neurofibromatosis type 1: a case with review of the literature. BMJ Case Rep 2019;12:bcr-2018-226702. [PMID: 30635305 DOI: 10.1136/bcr-2018-226702] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 162 |
Varas-lorenzo M, Cugat E, Capdevila J, Sánchez-vizcaíno Mengual E. Detection of pancreatic neuroendocrine tumors: 23 years of experience. Revista de Gastroenterología de México (English Edition) 2019;84:18-25. [DOI: 10.1016/j.rgmxen.2018.08.001] [Reference Citation Analysis]
|
| 163 |
Herrera-Martínez AD, Pedraza-Arevalo S, L-López F, Gahete MD, Gálvez-Moreno MA, Castaño JP, Luque RM. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution? J Clin Endocrinol Metab 2019;104:57-73. [PMID: 30265346 DOI: 10.1210/jc.2018-01455] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 164 |
Hackert T, Wüsten L, Büchler MW. Anti-angiogenics in Pancreatic Cancer Therapy. Tumor Angiogenesis 2019. [DOI: 10.1007/978-3-319-33673-2_18] [Reference Citation Analysis]
|
| 165 |
Yasir S. Special Forms of Gastritis. Surgical Pathology of Non-neoplastic Gastrointestinal Diseases 2019. [DOI: 10.1007/978-3-030-15573-5_7] [Reference Citation Analysis]
|
| 166 |
Chen WC, Warner RRP, Harpaz N, Zhu H, Roayaie S, Kim MK. Gastric Neuroendocrine Tumor and Duodenal Gastrinoma With Chronic Autoimmune Atrophic Gastritis. Pancreas 2019;48:131-4. [PMID: 30531243 DOI: 10.1097/MPA.0000000000001204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 167 |
Oh H, Paik WH, Song TJ, Seo DW. Ablation of Tumor Using EUS. Advanced Therapeutic Endoscopy for Pancreatico-Biliary Diseases 2019. [DOI: 10.1007/978-4-431-56009-8_13] [Reference Citation Analysis]
|
| 168 |
Dillhoff ME, Ellison EC. Zollinger-Ellison Syndrome. Shackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019. [DOI: 10.1016/b978-0-323-40232-3.00060-1] [Reference Citation Analysis]
|
| 169 |
Nandhini LP, Kamalanathan S, Sahoo J. Definition, Diagnostic Criteria, Screening, Diagnosis, and Classification of Diabetes and Categories of Glucose Intolerance. The Diabetes Textbook 2019. [DOI: 10.1007/978-3-030-11815-0_6] [Reference Citation Analysis]
|
| 170 |
Srivani G, Dariya B, Farran B, Alam A, Nagaraju GP. Biology of Pancreas and Possible Diseases. Exploring Pancreatic Metabolism and Malignancy 2019. [DOI: 10.1007/978-981-32-9393-9_1] [Reference Citation Analysis]
|
| 171 |
Guilmette JM, Nosé V. Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. Adv Anat Pathol 2019;26:13-30. [PMID: 29912000 DOI: 10.1097/PAP.0000000000000201] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
|
| 172 |
Baiu I, Azagury DE. Risk Factor Modification in Patients with Peptic Ulcer Disease. The SAGES Manual of Foregut Surgery 2019. [DOI: 10.1007/978-3-319-96122-4_54] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 173 |
Ryabin NS, Katrich AN, Bykov MI, Stash RG. THE POSSIBILITIES OF ENDOSCOPIC ULTRASONOGRAPHY IN THE DIAGNOSTICS OF SOLID PANCREATIC NEOPLASMS. Kuban nauсh med vestnik 2018;25:177-183. [DOI: 10.25207/1608-6228-2018-25-6-177-183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 174 |
Yu X, Gu J, Wu H, Fu D, Li J, Jin C. Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Oncol. 2018;2018:6273947. [PMID: 30538745 DOI: 10.1155/2018/6273947] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 175 |
Gao F, Zafar MI, Jüttner S, Höcker M, Wiedenmann B. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Med Sci Monit 2018;24:8125-40. [PMID: 30420588 DOI: 10.12659/MSM.912419] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 176 |
Lee NJ, Hruban RH, Fishman EK. Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance. Abdom Radiol (NY) 2018;43:3025-34. [PMID: 29594467 DOI: 10.1007/s00261-018-1574-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 177 |
Shao S, Zeng Z, Hu S. An observational analysis of insulinoma from a single institution. QJM 2018;111:237-41. [PMID: 29319794 DOI: 10.1093/qjmed/hcy006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 178 |
Ignatyuk VG, Britvin TA, Podrez DV, Gurevich LE. Multiple endocrine neoplasia type 1 with primary hyperparathyroidism, pancreatic insulinoma and portal gastrinoma (case report). Ann hir gepatol 2018;23:57-63. [DOI: 10.16931/1995-5464.2018357-63] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 179 |
Song Y, Gao S, Tan W, Qiu Z, Zhou H, Zhao Y. Multiple Machine Learnings Revealed Similar Predictive Accuracy for Prognosis of PNETs from the Surveillance, Epidemiology, and End Result Database. J Cancer 2018;9:3971-8. [PMID: 30410601 DOI: 10.7150/jca.26649] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 180 |
Grazzini G, Danti G, Cozzi D, Lanzetta MM, Addeo G, Falchini M, Masserelli A, Pradella S, Miele V. Diagnostic imaging of gastrointestinal neuroendocrine tumours (GI-NETs): relationship between MDCT features and 2010 WHO classification. Radiol Med 2019;124:94-102. [PMID: 30255371 DOI: 10.1007/s11547-018-0946-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 181 |
Varela D, Yu A, Saxon D. Insulinoma Masquerading as Transient Neurocognitive Impairment. Am J Med 2018;131:e377-9. [PMID: 29753794 DOI: 10.1016/j.amjmed.2018.04.031] [Reference Citation Analysis]
|
| 182 |
Kim C, Jeong DE, Heo S, Ji E, Rho JG, Jung M, Ahn S, Kim YJ, Kim YS, Nam SW, Kulkarni RN, Lee KB, Lee EK, Kim W. Reduced expression of the RNA-binding protein HuD in pancreatic neuroendocrine tumors correlates with low p27Kip1 levels and poor prognosis. J Pathol 2018;246:231-43. [PMID: 30014466 DOI: 10.1002/path.5135] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 183 |
Genc CG, Klümpen HJ, van Oijen MGH, van Eijck CHJ, Nieveen van Dijkum EJM. A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands. World J Surg 2018;42:490-7. [PMID: 29018912 DOI: 10.1007/s00268-017-4278-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 184 |
Mintziras I, Keck T, Werner J, Fichtner-feigl S, Wittel U, Senninger N, Vowinkel T, Köninger J, Anthuber M, Geißler B, Bartsch DK; for the StuDoQ|Pancreas study group of the German Society for General and Visceral Surgery (DGAV). Implementation of Current ENETS Guidelines for Surgery of Small (≤2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry. World J Surg 2019;43:175-82. [DOI: 10.1007/s00268-018-4751-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 185 |
Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther 2018;18:837-60. [PMID: 29973077 DOI: 10.1080/14737140.2018.1496822] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 186 |
Miao DL, Song W, Qian J, Zhu ZG, Wu Q, Lv CG, Chen L. Development and Validation of a Nomogram for Predicting Overall Survival in Pancreatic NeuroendocrineTumors. Transl Oncol 2018;11:1097-103. [PMID: 30015262 DOI: 10.1016/j.tranon.2018.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 187 |
Yang Y, Yang L, Li Y. Neuropilin-1 (NRP-1) upregulated by IL-6/STAT3 signaling contributes to invasion in pancreatic neuroendocrine neoplasms. Hum Pathol. 2018;81:192-200. [PMID: 30420046 DOI: 10.1016/j.humpath.2018.06.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 188 |
Bezerra ROF, Machado MC, dos Santos Mota MM, Ezzedine TA, Siqueira LTDB, Cerri GG. Rare pancreatic masses: a pictorial review of radiological concepts. Clinical Imaging 2018;50:314-23. [DOI: 10.1016/j.clinimag.2018.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 189 |
Huang PY, Tsai KL, Liang CM, Tai WC, Rau KM, Wu KL, Huang CC, Chuah SK. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms. Kaohsiung J Med Sci 2018;34:650-6. [PMID: 30392572 DOI: 10.1016/j.kjms.2018.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 190 |
Varas-Lorenzo MJ, Cugat E, Capdevila J, Sánchez-Vizcaíno Mengual E. Detection of pancreatic neuroendocrine tumors: 23 years of experience. Rev Gastroenterol Mex (Engl Ed) 2019;84:18-25. [PMID: 29858120 DOI: 10.1016/j.rgmx.2018.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 191 |
Deng BY, Liu F, Yin SN, Chen AP, Xu L, Li B. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification. Clin Res Hepatol Gastroenterol 2018;42:261-8. [PMID: 29307515 DOI: 10.1016/j.clinre.2017.09.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 192 |
Tseng CM, Cheng TY, Chen TB, Tien YW, Chen CC, Lin JT, Wang HP. Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors. Oncol Lett 2018;15:8951-8. [PMID: 29805630 DOI: 10.3892/ol.2018.8472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 193 |
Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018;19:909-28. [PMID: 29757017 DOI: 10.1080/14656566.2018.1476492] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 194 |
Qin S, Liu Y, Ning H, Tao L, Luo W, Lu D, Luo Z, Qin Y, Zhou J, Chen J, Jiang H. EUS-guided lauromacrogol ablation of insulinomas: a novel treatment. Scand J Gastroenterol 2018;53:616-20. [PMID: 29141488 DOI: 10.1080/00365521.2017.1402206] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 195 |
Belfiori G, Wiese D, Partelli S, Wächter S, Maurer E, Crippa S, Falconi M, Bartsch DK. Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes. World J Surg 2018;42:3223-30. [DOI: 10.1007/s00268-018-4628-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 196 |
Raj N, Shah R, Stadler Z, Mukherjee S, Chou J, Untch B, Li J, Kelly V, Saltz LB, Mandelker D, Ladanyi M, Berger MF, Klimstra DS, Reidy-Lagunes D, Osoba M. Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability. JCO Precis Oncol 2018;2018. [PMID: 30687805 DOI: 10.1200/PO.17.00267] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 197 |
Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. Tumori 2019;105:113-20. [DOI: 10.1177/0300891618765362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 198 |
Zhang J, Jin J, Chen S, Gu J, Zhu Y, Qin K, Zhan Q, Cheng D, Chen H, Deng X, Shen B, Peng C. Minimally invasive distal pancreatectomy for PNETs: laparoscopic or robotic approach? Oncotarget 2017;8:33872-83. [PMID: 28477012 DOI: 10.18632/oncotarget.17513] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 199 |
Philips P, Kooby DA, Maithel S, Merchant NB, Weber SM, Winslow ER, Ahmad S, Kim HJ, Scoggins CR, McMasters KM, Martin RCG 2nd. Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors. Pancreas 2018;47:326-31. [PMID: 29351120 DOI: 10.1097/MPA.0000000000000990] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 200 |
Sallinen VJ, Le Large TYS, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik SP, Antila A, Franklin O, Martinez-Moneo E, Robinson SM, Panzuto F, Regenet N, Muffatti F, Partelli S, Wiese D, Ruszniewski P, Dousset B, Edwin B, Bartsch DK, Sauvanet A, Falconi M, Ceyhan GO, Gaujoux S; Pancreas 2000 research group. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study. HPB (Oxford) 2018;20:251-9. [PMID: 28988702 DOI: 10.1016/j.hpb.2017.08.034] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 14.0] [Reference Citation Analysis]
|
| 201 |
Tadman M, Charlton P, Jafar-Mohammadi B, Talbot D, Grossman AB. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE. Endocr Pract 2018;24:189-94. [PMID: 29466059 DOI: 10.4158/EP-2017-0137] [Reference Citation Analysis]
|
| 202 |
Ueda K, Lee L, Ito T. Management of Insulinoma. The Pancreas 2018. [DOI: 10.1002/9781119188421.ch133] [Reference Citation Analysis]
|
| 203 |
Doi R. Rare Neuroendocrine Tumors of the Pancreas. The Pancreas 2018. [DOI: 10.1002/9781119188421.ch135] [Reference Citation Analysis]
|
| 204 |
Corrias G, Monti S, Horvat N, Tang L, Basturk O, Saba L, Mannelli L. Imaging features of malignant abdominal neuroendocrine tumors with rare presentation. Clin Imaging 2018;51:59-64. [PMID: 29448120 DOI: 10.1016/j.clinimag.2018.02.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 205 |
Long HY, Huang QX, Yu YY, Zhang ZB, Yao ZW, Chen HB, Feng JW. Dehydrocostus lactone inhibits in vitro gastrinoma cancer cell growth through apoptosis induction, sub-G1 cell cycle arrest, DNA damage and loss of mitochondrial membrane potential. Arch Med Sci 2019;15:765-73. [PMID: 31110544 DOI: 10.5114/aoms.2018.73128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 206 |
Shirota T, Nagakawa Y, Sahara Y, Takishita C, Hijikata Y, Hosokawa Y, Nakajima T, Osakabe H, Katsumata K, Tsuchida A. Surgical resection of neuroendocrine tumors of the pancreas (pNETs) by minimally invasive surgery: the laparoscopic approach. Gland Surg 2018;7:12-9. [PMID: 29629315 DOI: 10.21037/gs.2017.11.06] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 207 |
Shatveryan GA, Karagyozyan GA, Chardarov NK, Bagmet NN, Ratnikova NP. [Surgical management of non-functioning pancreatic neuroendocrine tumors]. Khirurgiia (Mosk) 2018;:4-9. [PMID: 29376950 DOI: 10.17116/hirurgia201814-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 208 |
Ligiero Braga T, Santos-Oliveira R. PPoma Review: Epidemiology, Aetiopathogenesis, Prognosis and Treatment. Diseases 2018;6:E8. [PMID: 29324681 DOI: 10.3390/diseases6010008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 209 |
Viúdez A, Carvalho FL, Maleki Z, Zahurak M, Laheru D, Stark A, Azad NS, Wolfgang CL, Baylin S, Herman JG, De Jesus-Acosta A. A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET). Oncotarget 2016;7:24950-61. [PMID: 26894863 DOI: 10.18632/oncotarget.7436] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 210 |
Yardımcı S, Özer İ, Dalgıç T, Turhan N, Bostancı EB. Symptomatic hepatic metastasis of insulinoma 15 years after pancreatic resection. Turk J Surg 2018;34:240-2. [PMID: 30302430 DOI: 10.5152/turkjsurg.2017.3276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 211 |
Dialer LO, Jodal A, Schibli R, Ametamey SM, Béhé M. Radiosynthesis and evaluation of an 18F-labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma. EJNMMI Radiopharm Chem 2018;3:1. [PMID: 29503858 DOI: 10.1186/s41181-017-0036-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 212 |
Appetecchia M, Lauretta R, Rota F, Carlini M. Sporadic Gastroenteropancreatic Neuroendocrine Tumors. Updates in Surgery 2018. [DOI: 10.1007/978-88-470-3955-1_4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 213 |
Zollinger-Ellison Syndrome. Imaging in Gastroenterology 2018. [DOI: 10.1016/b978-0-323-55408-4.50087-2] [Reference Citation Analysis]
|
| 214 |
Fendrich V, Bartsch DK. Sporadic Pancreatic Endocrine Tumors. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-7193-0_8] [Reference Citation Analysis]
|
| 215 |
Appetecchia M, Lauretta R, Rota F, Carlini M. Neuroendocrine Tumors Biomarkers. Updates in Surgery 2018. [DOI: 10.1007/978-88-470-3955-1_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 216 |
Pancreatic Neuroendocrine Tumor. Diagnostic Pathology: Cytopathology 2018. [DOI: 10.1016/b978-0-323-54763-5.50232-4] [Reference Citation Analysis]
|
| 217 |
Delle Fave G, Merola E, Capurso G, Festa S, Piciucchi M, Valente R. Molecular Pathology of Pancreatic Endocrine Tumors. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-7193-0_7] [Reference Citation Analysis]
|
| 218 |
Jensen RT. Gastrointestinal Neuroendocrine Tumor Syndromes (GI NETS). Encyclopedia of Endocrine Diseases 2018. [DOI: 10.1016/b978-0-12-801238-3.95870-7] [Reference Citation Analysis]
|
| 219 |
Sanguinetti A, Polistena A, Johnson LB, Avenia N. Pancreatic Neuroendocrine Tumors (pNETs). Surgical Management of Elderly Patients 2018. [DOI: 10.1007/978-3-319-60861-7_9] [Reference Citation Analysis]
|
| 220 |
Komoto I, Hosoda Y, Imamura M. Molecular Targeted Therapy for Gastroenteropancreatic Neuroendocrine Tumors. Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy 2018. [DOI: 10.1007/978-981-10-6469-2_9] [Reference Citation Analysis]
|
| 221 |
Costamagna G, Boškoski I, Attili F. Endoscopic Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumors. Updates in Surgery 2018. [DOI: 10.1007/978-88-470-3955-1_6] [Reference Citation Analysis]
|
| 222 |
Chew C, Bonney GK. Pancreatic Neuroendocrine Tumours. Evidence-Based Endocrine Surgery 2018. [DOI: 10.1007/978-981-10-1124-5_36] [Reference Citation Analysis]
|
| 223 |
Christians KK, Younan G, George B, Tsai S, Evans DB. Resection Versus Chemotherapy for Metastatic Neuroendocrine Tumors of the Pancreas. Difficult Decisions in Endocrine Surgery 2018. [DOI: 10.1007/978-3-319-92860-9_36] [Reference Citation Analysis]
|
| 224 |
Delle Fave G, Merola E, Capurso G, Festa S, Piciucchi M, Valente R. Molecular Pathology of Pancreatic Endocrine Tumors. Pancreatic Cancer 2018. [DOI: 10.1007/978-1-4939-6631-8_7-2] [Reference Citation Analysis]
|
| 225 |
Jensen RT. Gastrinomas. Encyclopedia of Endocrine Diseases 2018. [DOI: 10.1016/b978-0-12-801238-3.95869-0] [Reference Citation Analysis]
|
| 226 |
Rossi RE, Massironi S. Tumor Staging: Pancreas. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_15] [Reference Citation Analysis]
|
| 227 |
Kidd M, Ferone D, Albertelli M, Nazzari E, Bodei L, Modlin IM. The Molecular Biology of NET: Current Status and Evaluation of Biomarkers for Prediction and Prognosis. Neuroendocrine Tumors in Real Life 2018. [DOI: 10.1007/978-3-319-59024-0_3] [Reference Citation Analysis]
|
| 228 |
Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H. Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases. Turk J Surg 2017;33:279-83. [PMID: 29260133 DOI: 10.5152/UCD.2017.3685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 229 |
Lee DW, Kim MK, Kim HG. Diagnosis of Pancreatic Neuroendocrine Tumors. Clin Endosc. 2017;50:537-545. [PMID: 29207856 DOI: 10.5946/ce.2017.131] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 230 |
Kim K, Kim SJ. Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors. Nucl Med Mol Imaging 2018;52:208-15. [PMID: 29942399 DOI: 10.1007/s13139-017-0505-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 231 |
Foppiani L, Panarello S, Filauro M, Scirocco MC, Cappato S, Parodi A, Sola S, Antonucci G. Insulinoma and Chronic Kidney Disease: An Uncommon Conundrum Not to Be Overlooked. Clin Med Insights Endocrinol Diabetes 2017;10:1179551417742620. [PMID: 29200897 DOI: 10.1177/1179551417742620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 232 |
Cen D, Chen J, Li Z, Zhao J, Cai X. Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis. PLoS One 2017;12:e0187588. [PMID: 29136022 DOI: 10.1371/journal.pone.0187588] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 233 |
Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163:218-225. [PMID: 29103583 DOI: 10.1016/j.surg.2017.05.030] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 234 |
Verde F, Fishman EK. Calcified pancreatic and peripancreatic neoplasms: spectrum of pathologies. Abdom Radiol (NY) 2017;42:2686-97. [PMID: 28785786 DOI: 10.1007/s00261-017-1182-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 235 |
Ore AS, Barrows CE, Solis-Velasco M, Shaker J, Moser AJ. Robotic enucleation of benign pancreatic tumors. J Vis Surg 2017;3:151. [PMID: 29302427 DOI: 10.21037/jovs.2017.08.15] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 236 |
Lopez-Aguiar AG, Ethun CG, Postlewait LM, Zhelnin K, Krasinskas A, El-Rayes BF, Russell MC, Sarmiento JM, Kooby DA, Staley CA, Maithel SK, Cardona K. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. Ann Surg Oncol 2018;25:290-8. [PMID: 29079920 DOI: 10.1245/s10434-017-6140-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 237 |
Lykoudis PM, Partelli S, Muffatti F, Caplin M, Falconi M, Fusai GK; RARECARENet Working Group. Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. Eur J Surg Oncol 2019;45:46-51. [PMID: 29126671 DOI: 10.1016/j.ejso.2017.08.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 238 |
Metz DC, Cadiot G, Poitras P, Ito T, Jensen RT. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol 2017;4:167-85. [PMID: 29326808 DOI: 10.2217/ije-2017-0018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 239 |
Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, Faggiano A; NIKE group. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?Endocrine. 2018;60:15-27. [PMID: 29019150 DOI: 10.1007/s12020-017-1420-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 240 |
Sagami R, Nishikiori H, Ikuyama S, Murakami K. Rupture of small cystic pancreatic neuroendocrine tumor with many microtumors. World J Gastroenterol 2017; 23(37): 6911-6919 [PMID: 29085235 DOI: 10.3748/wjg.v23.i37.6911] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 241 |
Daly DM, Thompson B, Low J, Slater J, Wood G, Kamath V, Haghighi KS. Emergency pancreatic resection for glucagonoma associated with severe necrolytic migratory erythema. ANZ J Surg 2019;89:599-602. [PMID: 28982222 DOI: 10.1111/ans.14186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 242 |
Saunders RN, Chung M. Locally Recurrent Well-Differentiated Nonfunctioning Pancreatic Neuroendocrine Tumor Requiring Re-excision Including Portal Vein Resection. J Gastrointest Cancer 2019;50:324-7. [PMID: 28965184 DOI: 10.1007/s12029-017-0010-2] [Reference Citation Analysis]
|
| 243 |
Cavalcoli F, Garrahy A, Castellaneta M, Tamagno G. Epidemiology of Neuroendocrine Tumours: By Site of Tumour and by Geographical Area. In: Colao A, Faggiano A, de Herder W, editors. Neuroendocrine Tumors in Real Life. Cham: Springer International Publishing; 2018. pp. 3-27. [DOI: 10.1007/978-3-319-59024-0_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 244 |
Lee KJ, Cho JH, Lee SH, Song SY, Lee KH, Jeong S, Ryu JK, Woo SM, Bang S, Lee JK, Lee TH, Paik WH, Kim YT, Lee WJ. Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea. Cancer Chemother Pharmacol 2017;80:799-805. [DOI: 10.1007/s00280-017-3421-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 245 |
Dai H, Xu Q, Hong X, Wang X, Pang H, Wu W, Zhao Y. Surgery in overweight patients with insulinoma: effects on weight loss. Scand J Gastroenterol 2017;52:1037-41. [PMID: 28583047 DOI: 10.1080/00365521.2017.1335768] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 246 |
Mendelson AH, Donowitz M. Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome. Dig Dis Sci 2017;62:2258-65. [PMID: 28776139 DOI: 10.1007/s10620-017-4695-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 247 |
Yang M, Ke NW, Zhang Y, Tan CL, Tian BL, Liu XB, Huang W, Nunes Q, Sutton R. Functional and non-functional pancreatic neuroendocrine tumours: ENETS or AJCC TNM staging system? Oncotarget 2017;8:82784-95. [PMID: 29137302 DOI: 10.18632/oncotarget.20007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 248 |
Jang S, Jin H, Roy M, Ma AL, Gong S, Jaskula-Sztul R, Chen H. Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1. Cancer Med 2017;6:2142-52. [PMID: 28776955 DOI: 10.1002/cam4.1151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 249 |
Sato A, Masui T, Sankoda N, Nakano K, Uchida Y, Anazawa T, Takaori K, Kawaguchi Y, Uemoto S. A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor. Surg Case Rep 2017;3:82. [PMID: 28730577 DOI: 10.1186/s40792-017-0361-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 250 |
Raj N, Klimstra DS, Horvat N, Zhang L, Chou JF, Capanu M, Basturk O, Do RKG, Allen PJ, Reidy-Lagunes D. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. Pancreas 2017;46:758-63. [PMID: 28609363 DOI: 10.1097/MPA.0000000000000842] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 251 |
Aluri V, Dillon JS. Biochemical Testing in Neuroendocrine Tumors. Endocrinol Metab Clin North Am 2017;46:669-77. [PMID: 28760232 DOI: 10.1016/j.ecl.2017.04.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 252 |
Yonemori K, Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Ueno S, Shinchi H, Natsugoe S. Impact of Snail and E-cadherin expression in pancreatic neuroendocrine tumors. Oncol Lett 2017;14:1697-702. [PMID: 28789397 DOI: 10.3892/ol.2017.6306] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 253 |
Tong Z, Liu L, Zheng Y, Jiang W, Zhao P, Fang W, Wang W. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study. World J Surg Oncol 2017;15:108. [PMID: 28558772 DOI: 10.1186/s12957-017-1169-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 254 |
Song YL, Yu R, Qiao XW, Bai CM, Lu CM, Xiao Y, Zhong DR, Chen J, Zhao YP, Zhang TP, Song TT, Gao HL, Wan YH, Shen L, Chen J, Lv B, Hao JJ, Zhang Y, Tang L, Chen YJ. Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors. Sci Rep 2017;7:2205. [PMID: 28526880 DOI: 10.1038/s41598-017-02051-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 255 |
Neychev V, Kebebew E. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. Int J Surg Oncol 2017;2017:6424812. [PMID: 28593056 DOI: 10.1155/2017/6424812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 256 |
Antonuzzo L, Del Re M, Barucca V, Spada F, Meoni G, Restante G, Danesi R, Di Costanzo F, Fazio N. Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors. Cancer Treat Rev 2017;57:28-35. [PMID: 28535439 DOI: 10.1016/j.ctrv.2017.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 257 |
Kelgiorgi D, Dervenis C. Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target. F1000Res 2017;6:663. [PMID: 28529726 DOI: 10.12688/f1000research.10188.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 258 |
Mirkin KA, Hollenbeak CS, Wong J. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm. Journal of Surgical Research 2017;211:206-14. [DOI: 10.1016/j.jss.2016.12.033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 259 |
Hu J, Hu Q, Hu H. Characterization of single lesion nonfunctioning pancreatic neuroendocrine carcinoma via computed tomography. Oncol Lett 2017;13:2186-90. [PMID: 28454379 DOI: 10.3892/ol.2017.5729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 260 |
Bar-Moshe Y, Mazeh H, Grozinsky-Glasberg S. Non-functioning pancreatic neuroendocrine tumors: Surgery or observation? World J Gastrointest Endosc 2017; 9(4): 153-161 [PMID: 28465781 DOI: 10.4253/wjge.v9.i4.153] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 261 |
ElGuindy YM, Javadi S, Menias CO, Jensen CT, Elsamaloty H, Elsayes KM. Imaging of secretory tumors of the gastrointestinal tract. Abdom Radiol (NY) 2017;42:1113-31. [PMID: 27878636 DOI: 10.1007/s00261-016-0976-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 262 |
Arima K, Okabe H, Hashimoto D, Chikamoto A, Nitta H, Higashi T, Kaida T, Yamamura K, Kitano Y, Komohara Y, Yamashita YI, Beppu T, Takeya M, Baba H. Neutrophil-to-lymphocyte ratio predicts metachronous liver metastasis of pancreatic neuroendocrine tumors. Int J Clin Oncol. 2017;22:734-739. [PMID: 28285371 DOI: 10.1007/s10147-017-1111-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 263 |
Wang L, Matkar S, Xie G, An C, He X, Kong X, Liu X, Hua X. BRD4 inhibitor IBET upregulates p27kip/cip protein stability in neuroendocrine tumor cells. Cancer Biol Ther 2017;18:229-36. [PMID: 28281917 DOI: 10.1080/15384047.2017.1294291] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 264 |
Díaz Del Arco C, Díaz Pérez JÁ, Ortega Medina L, Sastre Valera J, Fernández Aceñero MJ. Reliability of Ki-67 Determination in FNA Samples for Grading Pancreatic Neuroendocrine Tumors. Endocr Pathol 2016;27:276-83. [PMID: 27688080 DOI: 10.1007/s12022-016-9455-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 265 |
Lenhart A, Hassan M, Meighani A, Sadiq O, Siddiqui Y. A Perplexing Case of Abdominal Pain That Led to the Diagnosis of Zollinger-Ellison Syndrome. Case Rep Gastrointest Med 2017;2017:7636952. [PMID: 28321346 DOI: 10.1155/2017/7636952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 266 |
Uribe Galeano C, Fabregat Prous J, Busquets Barenys J, Pelaez Serra N, Secanella Medayo L, Ramos Rubio E, Ruiz Osuna S, Villabona Artero C. Nonfunctioning, small, incidental pancreatic neuroendocrine tumors: Results of a nonoperative approach cohort. Cir Esp 2017;95:83-8. [PMID: 28162264 DOI: 10.1016/j.ciresp.2016.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 267 |
Uribe Galeano C, Fabregat Prous J, Busquets Barenys J, Pelaez Serra N, Secanella Medayo L, Ramos Rubio E, Ruiz Osuna S, Villabona Artero C. Nonfunctioning, Small, Incidental Pancreatic Neuroendocrine Tumors: Results of a Nonoperative Approach Cohort. Cirugía Española (English Edition) 2017;95:83-88. [DOI: 10.1016/j.cireng.2016.12.003] [Reference Citation Analysis]
|
| 268 |
Camilleri M, Sellin JH, Barrett KE. Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea. Gastroenterology 2017;152:515-532.e2. [PMID: 27773805 DOI: 10.1053/j.gastro.2016.10.014] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 11.2] [Reference Citation Analysis]
|
| 269 |
Zhu L, Wu W, Xue H, Liu W, Wang X, Sun H, Li P, Zhao Y, Jin Z. Sporadic insulinomas on volume perfusion CT: dynamic enhancement patterns and timing of optimal tumour–parenchyma contrast. Eur Radiol 2017;27:3491-8. [DOI: 10.1007/s00330-016-4709-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 270 |
Sakuma Y, Yasuda Y, Sata N, Hosoya Y, Shimizu A, Fujii H, Matsubara D, Fukushima N, Miki A, Maeno M, Lefor AK. Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report. BMC Cancer 2017;17:37. [PMID: 28068959 DOI: 10.1186/s12885-016-3020-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 271 |
Spoletini G, Tamburrino D, Muffatti F, Crippa S, Andreasi V, Partelli S, Falconi M. Guideline for the Management of Pancreatic Neuroendocrine Tumor. Pancreatic Cancer 2017. [DOI: 10.1007/978-3-662-47181-4_13] [Reference Citation Analysis]
|
| 272 |
Hackert T, Wüsten L, Büchler MW. Anti-Angiogenics in Pancreatic Cancer Therapy. Tumor Angiogenesis 2017. [DOI: 10.1007/978-3-319-31215-6_18-1] [Reference Citation Analysis]
|
| 273 |
Rorstad OP. Neuroendocrine tumors. Endocrine Biomarkers 2017. [DOI: 10.1016/b978-0-12-803412-5.00009-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 274 |
Bodei L, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors. Nuclear Oncology 2017. [DOI: 10.1007/978-3-319-26236-9_18] [Reference Citation Analysis]
|
| 275 |
Aamar A, Madhani K, Virk H, Butt Z. Zollinger-Ellison Syndrome: A Rare Case of Chronic Diarrhea.Gastroenterology Res. 2016;9:103-104. [PMID: 28058079 DOI: 10.14740/gr734w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 276 |
Cheng Y, Zhan H, Wang L, Xu J, Zhang G, Zhang Z, Hu S. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes. Front Med 2016;10:444-50. [DOI: 10.1007/s11684-016-0471-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 277 |
Jiang Y, Jin JB, Zhan Q, Deng XX, Shen BY. Impact and Clinical Predictors of Lymph Node Metastases in Nonfunctional Pancreatic Neuroendocrine Tumors. Chin Med J (Engl). 2015;128:3335-3344. [PMID: 26668149 DOI: 10.4103/0366-6999.171427] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 278 |
Jennings RE, Hanley NA. Endocrine Disorders that Cause Diabetes. Textbook of Diabetes 2016. [DOI: 10.1002/9781118924853.ch20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 279 |
Díaz del Arco C, Esteban López-jamar JM, Ortega Medina L, Díaz Pérez JÁ, Fernández Aceñero MJ. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior: GRADING OF PANCREATIC NEUROENDOCRINE TUMORS IN FNA SAMPLES. Diagn Cytopathol 2017;45:29-35. [DOI: 10.1002/dc.23635] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 280 |
Nanno Y, Matsumoto I, Zen Y, Otani K, Uemura J, Toyama H, Asari S, Goto T, Ajiki T, Okano K, Suzuki Y, Takeyama Y, Fukumoto T, Ku Y. Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor. Ann Surg Oncol 2017;24:1127-33. [DOI: 10.1245/s10434-016-5663-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 281 |
Craven KE, Gore J, Wilson JL, Korc M. Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes. Oncotarget 2016;7:323-41. [PMID: 26586478 DOI: 10.18632/oncotarget.6345] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 282 |
Bergsland EK, Woltering EA, Rindi G, O’dorisio TM, Schilsky RL, Liu EH, Kim MK, Nakakura EK, Reidy-lagunes DL, Strosberg JR, Tang LH, Vinik AI, Wang Y, Asare EA, Brierley JD, Bushnell DL, Jensen RT, Pommier RF, Wolin EM, Wong RK, Klimstra DS. Neuroendocrine Tumors of the Pancreas. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. Cham: Springer International Publishing; 2017. pp. 407-19. [DOI: 10.1007/978-3-319-40618-3_34] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 283 |
Sánchez-bueno F, Rodríguez González JM, Torres Salmerón G, Bernabé Peñalver A, Balsalobre Salmeron M, de la Peña Moral J, Fuster Quiñonero M, Parrilla Paricio P. Factores pronósticos de los tumores neuroendocrinos de páncreas resecados. Experiencia en 95 pacientes. Cirugía Española 2016;94:473-80. [DOI: 10.1016/j.ciresp.2016.05.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 284 |
Sánchez-bueno F, Rodríguez González JM, Torres Salmerón G, Bernabé Peñalver A, Balsalobre Salmeron M, de la Peña Moral J, Fuster Quiñonero M, Parrilla Paricio P. Prognostic Factors in Resected Pancreatic Neuroendocrine Tumours: Experience in 95 Patients. Cirugía Española (English Edition) 2016;94:473-480. [DOI: 10.1016/j.cireng.2016.09.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 285 |
Fujimori N, Osoegawa T, Lee L, Tachibana Y, Aso A, Kubo H, Kawabe K, Igarashi H, Nakamura K, Oda Y, Ito T. Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors. Scand J Gastroenterol 2016;51:245-52. [PMID: 26513346 DOI: 10.3109/00365521.2015.1083050] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 286 |
Calin ML, Sadiq A, Arevalo G, Fuentes R, Flanders VL, Gupta N, Nasri B, Singh K. The First Case Report of Robotic Multivisceral Resection for Synchronous Liver Metastasis from Pancreatic Neuroendocrine Tumor: A Case Report and Literature Review. J Laparoendosc Adv Surg Tech A 2016;26:816-24. [PMID: 27454160 DOI: 10.1089/lap.2016.0342] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 287 |
Parbhu SK, Adler DG. Pancreatic neuroendocrine tumors: contemporary diagnosis and management. Hosp Pract (1995) 2016;44:109-19. [PMID: 27404266 DOI: 10.1080/21548331.2016.1210474] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 288 |
Caldas AR, Teixeira S, Giestas A, Amaral C, Cardoso MH. Insulinoma pancreático: casuística de um hospital central e revisão da literatura. Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo 2016;11:181-187. [DOI: 10.1016/j.rpedm.2015.06.002] [Reference Citation Analysis]
|
| 289 |
Zhu LM, Tang L, Qiao XW, Wolin E, Nissen NN, Dhall D, Chen J, Shen L, Chi Y, Yuan YZ, Ben QW, Lv B, Zhou YR, Bai CM, Chen J, Song YL, Song TT, Lu CM, Yu R, Chen YJ. Differences and Similarities in the Clinicopathological Features of Pancreatic Neuroendocrine Tumors in China and the United States: A Multicenter Study. Medicine (Baltimore) 2016;95:e2836. [PMID: 26886644 DOI: 10.1097/MD.0000000000002836] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 290 |
Postlewait LM, Ethun CG, Baptiste GG, Le N, Mcinnis MR, Cardona K, Russell MC, Sarmiento JM, Kooby DA, Staley CA, Maithel SK. Pancreatic neuroendocrine tumors: Preoperative factors that predict lymph node metastases to guide operative strategy: Pancreatic Neuroendocrine Tumors. J Surg Oncol 2016;114:440-5. [DOI: 10.1002/jso.24338] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 291 |
Karakaxas D, Sioziou A, Aravantinos G, Coker A, Papanikolaou IS, Liakakos T, Dervenis C, Gazouli M. Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility. World J Gastrointest Oncol 2016; 8(6): 520-525 [PMID: 27326321 DOI: 10.4251/wjgo.v8.i6.520] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 292 |
Alshikho MJ, Noureldine SI, Talas JM, Nasimian A, Zazou S, Mobaed B, Nasser M. Zollinger-Ellison Syndrome Associated with von Recklinghausen Disease: Case Report and Literature Review. Am J Case Rep 2016;17:398-405. [PMID: 27292293 DOI: 10.12659/ajcr.898472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 293 |
Gincul R. Tumeurs neuroendocrines pancréatiques. Acta Endosc 2016;46:250-253. [DOI: 10.1007/s10190-016-0547-4] [Reference Citation Analysis]
|
| 294 |
Watley DC, Ly QP, Talmon G, Are C, Sasson AR. Clinical presentation and outcome of nonfunctional pancreatic neuroendocrine tumors in a modern cohort. Am J Surg 2015;210:1192-5; discussion 1195-6. [PMID: 26674063 DOI: 10.1016/j.amjsurg.2015.08.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 295 |
Chiruvella A, Kooby DA. Surgical Management of Pancreatic Neuroendocrine Tumors. Surgical Oncology Clinics of North America 2016;25:401-21. [DOI: 10.1016/j.soc.2015.12.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 296 |
Folkert IW, Hernandez P, Roses RE. Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas. World J Gastroenterol 2016; 22(11): 3105-3116 [PMID: 27003988 DOI: 10.3748/wjg.v22.i11.3105] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 297 |
Viúdez A, De Jesus-Acosta A, Carvalho FL, Vera R, Martín-Algarra S, Ramírez N. Pancreatic neuroendocrine tumors: Challenges in an underestimated disease. Crit Rev Oncol Hematol 2016;101:193-206. [PMID: 27021395 DOI: 10.1016/j.critrevonc.2016.03.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 298 |
Jaskula-Sztul R, Xu W, Chen G, Harrison A, Dammalapati A, Nair R, Cheng Y, Gong S, Chen H. Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy. Biomaterials 2016;91:1-10. [PMID: 26994874 DOI: 10.1016/j.biomaterials.2016.03.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 299 |
Amin S, Kim MK. Islet Cell Tumors of the Pancreas. Gastroenterol Clin North Am 2016;45:83-100. [PMID: 26895682 DOI: 10.1016/j.gtc.2015.10.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 300 |
Shanahan MA, Salem A, Fisher A, Cho CS, Leverson G, Winslow ER, Weber SM. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors. Journal of Surgical Research 2016;201:38-43. [DOI: 10.1016/j.jss.2015.10.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 301 |
Polvani S, Tarocchi M, Tempesti S, Bencini L, Galli A. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World J Gastroenterol 2016; 22(8): 2441-2459 [PMID: 26937133 DOI: 10.3748/wjg.v22.i8.2441] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 302 |
Anderson CW, Bennett JJ. Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am. 2016;25:363-374. [PMID: 27013370 DOI: 10.1016/j.soc.2015.12.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 303 |
Ende AR, Sedarat A, Shah P, Jhala N, Fraker DL, Drebin JA, Metz DC, Kochman ML. Risk factors for aggressive nonfunctional pancreatic neuroendocrine tumors and the role of endoscopic ultrasound guided fine-needle aspiration. Endosc Ultrasound. 2016;5:49-54. [PMID: 26879167 DOI: 10.4103/2303-9027.175897] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 304 |
Armellini E, Crinò SF, Ballarè M, Pallio S, Occhipinti P. Endoscopic ultrasound-guided ethanol ablation of pancreatic neuroendocrine tumours: A case study and literature review. World J Gastrointest Endosc 2016; 8(3): 192-197 [PMID: 26862370 DOI: 10.4253/wjge.v8.i3.192] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 305 |
Yu R. Animal models of spontaneous pancreatic neuroendocrine tumors. Molecular and Cellular Endocrinology 2016;421:60-7. [DOI: 10.1016/j.mce.2015.08.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 306 |
Scialpi M, Reginelli A, D'Andrea A, Gravante S, Falcone G, Baccari P, Manganaro L, Palumbo B, Cappabianca S. Pancreatic tumors imaging: An update. Int J Surg. 2016;28 Suppl 1:S142-S155. [PMID: 26777740 DOI: 10.1016/j.ijsu.2015.12.053] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 307 |
Gad SF, Sicklick JK. Management of Pancreatic Gastrinoma. Difficult Decisions in Surgery: An Evidence-Based Approach 2016. [DOI: 10.1007/978-3-319-27365-5_57] [Reference Citation Analysis]
|
| 308 |
Hendifar AE, Liu S, Wolin E. The Role of mTOR Inhibitors in Neuroendocrine Tumors. mTOR Inhibition for Cancer Therapy: Past, Present and Future 2016. [DOI: 10.1007/978-2-8178-0492-7_5] [Reference Citation Analysis]
|
| 309 |
Mori H, Kaneoka Y, Maeda A, Takayama Y, Fukami Y, Onoe S. Laparoscopic distal pancreatectomy for a large insulinoma with a glucagonoma component. Journal of the Japan Pancreas Society 2016;31:145-149. [DOI: 10.2958/suizo.31.145] [Reference Citation Analysis]
|
| 310 |
Mcauliffe JC, Christein JD. Incidentalomas of the Pancreas. Current Controversies in Cancer Care for the Surgeon 2016. [DOI: 10.1007/978-3-319-16205-8_6] [Reference Citation Analysis]
|
| 311 |
Bodei L, Kidd M, Gilardi L, Volterrani D, Paganelli G, Grana CM, Modlin IM. Diagnostic Applications of Nuclear Medicine: Neuroendocrine Tumors. Nuclear Oncology 2016. [DOI: 10.1007/978-3-319-26067-9_18-1] [Reference Citation Analysis]
|
| 312 |
Grisotti G, Khan SA. Management of Small Nonfunctional Pancreatic Neuroendocrine Tumors. Difficult Decisions in Surgery: An Evidence-Based Approach 2016. [DOI: 10.1007/978-3-319-27365-5_56] [Reference Citation Analysis]
|
| 313 |
Bartel M, Di Leo M, Raimondo M. Differential Diagnosis and Diagnostic Evaluation Algorithm. Pancreatic Masses 2016. [DOI: 10.1007/978-3-319-19677-0_16] [Reference Citation Analysis]
|
| 314 |
Sheikh U, Muhammad J, Coppola D, Nasir A. Molecular Targets in Human Neuroendocrine Tumors. Neuroendocrine Tumors: Review of Pathology, Molecular and Therapeutic Advances 2016. [DOI: 10.1007/978-1-4939-3426-3_26] [Reference Citation Analysis]
|
| 315 |
Fendrich V, Bartsch DK. Sporadic Pancreatic Endocrine Tumors. Pancreatic Cancer 2016. [DOI: 10.1007/978-1-4939-6631-8_8-2] [Reference Citation Analysis]
|
| 316 |
Chawla S, Mekaroonkamol P, Willingham FF. Less Common Solid Tumors of Pancreas. Pancreatic Masses 2016. [DOI: 10.1007/978-3-319-19677-0_3] [Reference Citation Analysis]
|
| 317 |
Orditura M, Petrillo A, Ventriglia J, Diana A, Laterza MM, Fabozzi A, Savastano B, Franzese E, Conzo G, Santini L, Ciardiello F, De Vita F. Pancreatic neuroendocrine tumors: Nosography, management and treatment. Int J Surg. 2016;28 Suppl 1:S156-S162. [PMID: 26708853 DOI: 10.1016/j.ijsu.2015.12.052] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 318 |
Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16:e435-e446. [PMID: 26370353 DOI: 10.1016/s1470-2045(15)00186-2] [Cited by in Crossref: 161] [Cited by in F6Publishing: 142] [Article Influence: 20.1] [Reference Citation Analysis]
|
| 319 |
Gurung B, Hua X, Runske M, Bennett B, LiVolsi V, Roses R, Fraker DA, Metz DC. PTCH 1 staining of pancreatic neuroendocrine tumor (PNET) samples from patients with and without multiple endocrine neoplasia (MEN-1) syndrome reveals a potential therapeutic target. Cancer Biol Ther. 2015;16:219-224. [PMID: 25482929 DOI: 10.4161/15384047.2014.987574] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 320 |
Jensen RT. Zollinger–Ellison Syndrome. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch57] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 321 |
Carolan PJ, Chung DC. Neuroendocrine Tumors of the Pancreas. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch88] [Reference Citation Analysis]
|
| 322 |
Laliotis A, Martin J, Worthington TR, Marshall M, Isla AM. A novel technique of needle-guided laparoscopic enucleation of insulinomas. Surg Laparosc Endosc Percutan Tech. 2015;25:e24-e26. [PMID: 24743673 DOI: 10.1097/sle.0000000000000010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 323 |
Antonakis PT, Ashrafian H, Martinez-Isla A. Pancreatic insulinomas: Laparoscopic management. World J Gastrointest Endosc 2015; 7(16): 1197-1207 [PMID: 26566426 DOI: 10.4253/wjge.v7.i16.1197] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 324 |
Rosenberg AM, Friedmann P, Del Rivero J, Libutti SK, Laird AM. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors. Surgery. 2016;159:302-309. [PMID: 26547726 DOI: 10.1016/j.surg.2015.10.013] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 7.6] [Reference Citation Analysis]
|
| 325 |
Bartsch DK, Albers MB. Controversies in surgery for multiple endocrine neoplasia type 1-associated Zollinger–Ellison syndrome. International Journal of Endocrine Oncology 2015;2:263-71. [DOI: 10.2217/ije.15.17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 326 |
Holwerda RA, Walker CM, Rosado-de-christenson ML, Martínez-jiménez S, Kunin JR, Pettavel PP, Betancourt SL. Thoracic Metastases From Primary Hepatobiliary and Pancreatic Malignancies: Predictable Patterns of Metastatic Spread. Journal of Thoracic Imaging 2015;30:W82-91. [DOI: 10.1097/rti.0000000000000189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 327 |
Vinik AI, Chaya C. Clinical Presentation and Diagnosis of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016;30:21-48. [PMID: 26614367 DOI: 10.1016/j.hoc.2015.08.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 328 |
Raj N, Reidy-Lagunes D. Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30:119-133. [PMID: 26614372 DOI: 10.1016/j.hoc.2015.09.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 329 |
Balachandran A, Bhosale PR, Charnsangavej C, Tamm EP. Imaging of pancreatic neoplasms. Surg Oncol Clin N Am. 2014;23:751-788. [PMID: 25246049 DOI: 10.1016/j.soc.2014.07.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 330 |
Paniccia A, Edil BH, Schulick RD. Pancreatic Neuroendocrine Tumors: an Update. Indian J Surg 2015;77:395-402. [PMID: 26722203 DOI: 10.1007/s12262-015-1360-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 331 |
Manuel Vázquez A, Sanz Muñoz P, López López B, Carabias Hernández A, Jover Navalón JM. Diagnostic/Therapeutic Management of Pancreatic Neuroendocrine Tumours Associated with MEN 1 Syndrome. Cirugía Española (English Edition) 2015;93:539-541. [DOI: 10.1016/j.cireng.2015.04.003] [Reference Citation Analysis]
|
| 332 |
Ambrosini V, Campana D, Polverari G, Peterle C, Diodato S, Ricci C, Allegri V, Casadei R, Tomassetti P, Fanti S. Prognostic Value of 68 Ga-DOTANOC PET/CT SUV max in Patients with Neuroendocrine Tumors of the Pancreas. J Nucl Med 2015;56:1843-8. [DOI: 10.2967/jnumed.115.162719] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 333 |
Jung JG, Lee KT, Woo YS, Lee JK, Lee KH, Jang KT, Rhee JC. Behavior of Small, Asymptomatic, Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PNETs). Medicine (Baltimore) 2015;94:e983. [PMID: 26131843 DOI: 10.1097/MD.0000000000000983] [Cited by in Crossref: 35] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 334 |
Lee L, Igarashi H, Fujimori N, Hijioka M, Kawabe K, Oda Y, Jensen RT, Ito T. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. Jpn J Clin Oncol 2015;45:1131-8. [PMID: 26378090 DOI: 10.1093/jjco/hyv143] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 335 |
Caglià P, Cannizzaro MT, Tracia A, Amodeo L, Tracia L, Buffone A, Amodeo C, Cannizzaro MA. Cystic pancreatic neuroendocrine tumors: To date a diagnostic challenge. International Journal of Surgery 2015;21:S44-9. [DOI: 10.1016/j.ijsu.2015.04.087] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 336 |
Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World J Gastroenterol 2015; 21(32): 9512-9525 [PMID: 26327759 DOI: 10.3748/wjg.v21.i32.9512] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 82] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 337 |
Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am J Gastroenterol 2015;110:1223-32. [PMID: 26032155 DOI: 10.1038/ajg.2015.160] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 338 |
Cherif R, Gaujoux S, Cros J, Ruszniewski P, Sauvanet A. Parenchyma-sparing pancreatectomies for pancreatic neuroendocrine tumors. International Journal of Endocrine Oncology 2015;2:217-27. [DOI: 10.2217/ije.15.1] [Reference Citation Analysis]
|
| 339 |
Hüttner FJ, Schneider L, Tarantino I, Warschkow R, Schmied BM, Hackert T, Diener MK, Büchler MW, Ulrich A. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. Langenbecks Arch Surg. 2015;400:715-723. [PMID: 26198970 DOI: 10.1007/s00423-015-1323-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 340 |
Mauriello C, Napolitano S, Gambardella C, Candela G, De Vita F, Orditura M, Sciascia V, Tartaglia E, Lanza M, Santini L, Conzo G. Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review. Int J Surg 2015;21 Suppl 1:S10-4. [PMID: 26118605 DOI: 10.1016/j.ijsu.2015.04.089] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 341 |
Manuel Vázquez A, Sanz Muñoz P, López López B, Carabias Hernández A, Jover Navalón JM. Diagnostic/therapeutic management of pancreatic neuroendocrine tumours associated with MEN 1 syndrome. Cir Esp 2015;93:539-41. [PMID: 26051828 DOI: 10.1016/j.ciresp.2015.04.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 342 |
Passacantilli I, Capurso G, Archibugi L, Calabretta S, Caldarola S, Loreni F, Delle Fave G, Sette C. Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition. Oncotarget 2014;5:5381-91. [PMID: 25026292 DOI: 10.18632/oncotarget.2111] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 343 |
Humphrey PE, Alessandrino F, Bellizzi AM, Mortele KJ. Non-hyperfunctioning pancreatic endocrine tumors: multimodality imaging features with histopathological correlation. Abdom Imaging 2015;40:2398-410. [DOI: 10.1007/s00261-015-0458-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 344 |
Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open 2015;5:e008248. [PMID: 25991462 DOI: 10.1136/bmjopen-2015-008248] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 345 |
Kulke MH. Sequencing and Combining Systemic Therapies for Pancreatic Neuroendocrine Tumors. JCO 2015;33:1534-8. [DOI: 10.1200/jco.2014.59.0927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 346 |
Kim JY, Kim M, Kim K, Song K, Lee SH, Hwang DW, Kim K, Kim HJ, Yu E, Kim SC, Jang H, Hong S. Clinicopathologic and Prognostic Significance of Multiple Hormone Expression in Pancreatic Neuroendocrine Tumors. American Journal of Surgical Pathology 2015;39:592-601. [DOI: 10.1097/pas.0000000000000383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 347 |
Shi LN, Qiu ZL, Wu CG, Luo QY. A Rare Case of Calf Muscle Metastasis from a Non-Functional Pancreatic Neuroendocrine Carcinoma. Iran J Radiol 2015;12:e11637. [PMID: 26060551 DOI: 10.5812/iranjradiol.11637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 348 |
Wolf P, Winhofer Y, Smajis S, Anderwald C, Scheuba C, Niederle B, Gessl A, Luger A, Krebs M, Koperek O. Clinical presentation in insulinoma predicts histopathological tumour characteristics. Clin Endocrinol 2015;83:67-71. [DOI: 10.1111/cen.12777] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 349 |
Doi R. Determinants of surgical resection for pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2015;22:610-617. [PMID: 25773163 DOI: 10.1002/jhbp.224] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 350 |
Halfdanarson TR, Howe JR, Haraldsdottir S, O'dorisio TM. Circulating tumor markers in patients with neuroendocrine tumors – a clinical perspective. International Journal of Endocrine Oncology 2015;2:89-99. [DOI: 10.2217/ije.14.38] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 351 |
Chehade F, Ghosn M, Hammoud N, Mouharram G, Farhat F, Daher J, Jreige M, Haidar M. Approches de la médecine nucléaire au Liban dans les tumeurs neuroendocrines. Médecine Nucléaire 2015;39:e3-e13. [DOI: 10.1016/j.mednuc.2014.12.005] [Reference Citation Analysis]
|
| 352 |
Grozinsky-glasberg S, Mazeh H, Gross DJ. Clinical features of pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci 2015;22:578-85. [DOI: 10.1002/jhbp.226] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 353 |
Yang M, Zeng L, Zhang Y, Su AP, Yue PJ, Tian BL. Surgical treatment and clinical outcome of nonfunctional pancreatic neuroendocrine tumors: a 14-year experience from one single center. Medicine (Baltimore). 2014;93:e94. [PMID: 25396335 DOI: 10.1097/md.0000000000000094] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 354 |
Kidd M, Modlin IM, Bodei L, Drozdov I. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. Cell Mol Gastroenterol Hepatol 2015;1:131-53. [PMID: 28210673 DOI: 10.1016/j.jcmgh.2014.12.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 355 |
Hwang EJ, Lee JM, Yoon JH, Kim JH, Han JK, Choi BI, Lee KB, Jang JY, Kim SW, Nickel MD. Intravoxel incoherent motion diffusion-weighted imaging of pancreatic neuroendocrine tumors: prediction of the histologic grade using pure diffusion coefficient and tumor size. Invest Radiol. 2014;49:396-402. [PMID: 24500090 DOI: 10.1097/rli.0000000000000028] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 356 |
Nilubol N. Gastrinoma. Surgical Endocrinopathies 2015. [DOI: 10.1007/978-3-319-13662-2_47] [Reference Citation Analysis]
|
| 357 |
Pasieka JL, Chambers AJ. Gastrinoma. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_13] [Reference Citation Analysis]
|
| 358 |
Fendrich V, Bartsch DK. Endokrine Tumoren des Pankreas: Chirurgische Therapie. SpringerReference Innere Medizin 2015. [DOI: 10.1007/978-3-642-54676-1_555-1] [Reference Citation Analysis]
|
| 359 |
Yuditskaya S, Skarulis MC. Clinical Manifestations of Multiple Endocrine Neoplasia, Type 1. Management of Pancreatic Neuroendocrine Tumors 2015. [DOI: 10.1007/978-1-4939-1798-3_5] [Reference Citation Analysis]
|
| 360 |
Öberg K. Circulating Biomarkers in Neuroendocrine Tumours. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_7] [Reference Citation Analysis]
|
| 361 |
Raina A, Chandrasekhara V. Endoscopic Approaches to Treatment of Pancreatic Neuroendocrine Neoplasms. Management of Pancreatic Neuroendocrine Tumors 2015. [DOI: 10.1007/978-1-4939-1798-3_8] [Reference Citation Analysis]
|
| 362 |
Fishbein L, Nathanson KL. Inherited and Somatic Genetics of Pancreatic Neuroendocrine Tumors. Management of Pancreatic Neuroendocrine Tumors 2015. [DOI: 10.1007/978-1-4939-1798-3_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 363 |
Singh MH, Metz DC. Zollinger–Ellison Syndrome: Diagnosis and Management. Management of Pancreatic Neuroendocrine Tumors 2015. [DOI: 10.1007/978-1-4939-1798-3_4] [Reference Citation Analysis]
|
| 364 |
Park YS. Less Common Types of Pancreatic Neuroendocrine Tumors. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_17] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 365 |
Kartalis N, Mucelli RM, Sundin A. Recent developments in imaging of pancreatic neuroendocrine tumors. Ann Gastroenterol 2015;28:193-202. [PMID: 25830417] [Reference Citation Analysis]
|
| 366 |
Atema JJ, Jilesen AP, Busch OR, van Gulik TM, Gouma DJ, Nieveen van Dijkum EJ. Pancreatic fistulae after pancreatic resections for neuroendocrine tumours compared with resections for other lesions. HPB (Oxford) 2015;17:38-45. [PMID: 25041879 DOI: 10.1111/hpb.12319] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 367 |
Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K, Komoto I, Tanaka M, Imamura M, Jensen RT, Takayanagi R, Shimatsu A. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 2015;50:58-64. [PMID: 24499825 DOI: 10.1007/s00535-014-0934-2] [Cited by in Crossref: 247] [Cited by in F6Publishing: 249] [Article Influence: 30.9] [Reference Citation Analysis]
|
| 368 |
Williamson JML. Somatostatinoma. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_16] [Reference Citation Analysis]
|
| 369 |
Zollinger-Ellison Syndrome. Diagnostic Imaging: Gastrointestinal 2015. [DOI: 10.1016/b978-0-323-37755-3.50090-8] [Reference Citation Analysis]
|
| 370 |
Kilickap S, Hayran KM. Epidemiology of Neuroendocrine Tumors. Neuroendocrine Tumours 2015. [DOI: 10.1007/978-3-662-45215-8_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 371 |
Nishimura K, Oota S, Ikeyama T, Oomori K. Multiple Duodenal Gastrinoma Treated by Subtotal Stomach-preserving Pancreatoduodenectomy. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2015;48:993-1000. [DOI: 10.5833/jjgs.2015.0029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 372 |
Reid MD, Balci S, Saka B, Adsay NV. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr Pathol. 2014;25:65-79. [PMID: 24430597 DOI: 10.1007/s12022-013-9295-2] [Cited by in Crossref: 93] [Cited by in F6Publishing: 98] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 373 |
Gebauer N, Schmidt-Werthern C, Bernard V, Feller AC, Keck T, Begum N, Rades D, Lehnert H, Brabant G, Thorns C. Genomic landscape of pancreatic neuroendocrine tumors. World J Gastroenterol 2014; 20(46): 17498-17506 [PMID: 25516664 DOI: 10.3748/wjg.v20.i46.17498] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 374 |
Kondo NI, Ikeda Y. Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surg. 2014;3:276-283. [PMID: 25493259 DOI: 10.3978/j.issn.2227-684x.2013.12.05] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
|
| 375 |
McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3:258-275. [PMID: 25493258 DOI: 10.3978/j.issn.2227-684x.2014.06.03] [Cited by in F6Publishing: 31] [Reference Citation Analysis]
|
| 376 |
Raymond E, Faivre S. Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours. Curr Oncol. 2014;21:309-317. [PMID: 25489258 DOI: 10.3747/co.21.1647] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 377 |
Rosenbaum JN, Lloyd RV. Pancreatic Neuroendocrine Neoplasms. Surg Pathol Clin 2014;7:559-75. [PMID: 26837555 DOI: 10.1016/j.path.2014.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 378 |
Jones J, Knipe H. Zollinger-Ellison syndrome. Radiopaedia.org 2014. [DOI: 10.53347/rid-32256] [Reference Citation Analysis]
|
| 379 |
Warner RR. Neuroendocrine Tumors. Mount Sinai Expert Guides 2014. [DOI: 10.1002/9781118932759.ch28] [Reference Citation Analysis]
|
| 380 |
Rodriguez RA, Overton H, Morris KT. Pancreatic neuroendocrine tumor with splenic vein tumor thrombus: A case report. Int J Surg Case Rep 2014;5:1271-4. [PMID: 25460491 DOI: 10.1016/j.ijscr.2014.11.045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 381 |
Nakamura T, Igarashi H, Ito T, Jensen RT. Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example. World J Clin Cases 2014; 2(11): 608-613 [PMID: 25405184 DOI: 10.12998/wjcc.v2.i11.608] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 382 |
Cui MH, Branch CA, Cahill SM, Quinn TJ, Adem A, Libutti SK, Yuan Z. In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model. Magn Reson Med 2015;74:1221-6. [PMID: 25392979 DOI: 10.1002/mrm.25529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 383 |
Singh S, Dey C, Kennecke H, Kocha W, Maroun J, Metrakos P, Mukhtar T, Pasieka J, Rayson D, Rowsell C. Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Ann Surg Oncol. 2015;22:2685-2699. [PMID: 25366583 DOI: 10.1245/s10434-014-4145-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 66] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 384 |
Rustagi T, Farrell JJ. Endoscopic diagnosis and treatment of pancreatic neuroendocrine tumors. J Clin Gastroenterol 2014;48:837-44. [PMID: 24828360 DOI: 10.1097/MCG.0000000000000152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 385 |
Unno J, Kanno A, Masamune A, Kasajima A, Fujishima F, Ishida K, Hamada S, Kume K, Kikuta K, Hirota M, Motoi F, Unno M, Shimosegawa T. The usefulness of endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of pancreatic neuroendocrine tumors based on the World Health Organization classification. Scand J Gastroenterol 2014;49:1367-74. [PMID: 25180490 DOI: 10.3109/00365521.2014.934909] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 386 |
Vinik AI. Advances in Diagnosis and Treatment of Pancreatic Neuroendocrine Tumors. Endocrine Practice 2014;20:1222-30. [DOI: 10.4158/ep14373.ra] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 387 |
Ducreux M, Dahan L, Smith D, O’Toole D, Lepère C, Dromain C, Vilgrain V, Baudin E, Lombard-Bohas C, Scoazec JY. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial. Eur J Cancer. 2014;50:3098-3106. [PMID: 25454412 DOI: 10.1016/j.ejca.2014.10.002] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 388 |
Tsang YP, Lang BH, Shek TW. Assessing the short- and long-term outcomes after resection of benign insulinoma. ANZ J Surg 2016;86:706-10. [PMID: 25345822 DOI: 10.1111/ans.12891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 389 |
Rossi RE, Massironi S, Conte D, Peracchi M. Therapy for metastatic pancreatic neuroendocrine tumors. Ann Transl Med 2014;2:8. [PMID: 25332984 DOI: 10.3978/j.issn.2305-5839.2013.03.01] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
|
| 390 |
Shi C, Klimstra DS. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics. Semin Diagn Pathol 2014;31:498-511. [PMID: 25441311 DOI: 10.1053/j.semdp.2014.08.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 391 |
Kubota K, Okasaki M, Minamimoto R, Miyata Y, Morooka M, Nakajima K, Sato T. Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors. Ann Nucl Med. 2014;28:1004-1010. [PMID: 25179521 DOI: 10.1007/s12149-014-0900-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 392 |
Sofocleous CT, Petre EN, Gonen M, Reidy-Lagunes D, Ip IK, Alago W, Covey AM, Erinjeri JP, Brody LA, Maybody M, Thornton RH, Solomon SB, Getrajdman GI, Brown KT. Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases. J Vasc Interv Radiol 2014;25:22-30; quiz 31. [PMID: 24365504 DOI: 10.1016/j.jvir.2013.09.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 393 |
Fendrich V, Lopez CL, Manoharan J, Maschuw K, Wichmann S, Baier A, Holler JP, Ramaswamy A, Bartsch DK, Waldmann J. Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors. Endocrine Related Cancer 2014;21:813-24. [DOI: 10.1530/erc-14-0175] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 394 |
Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, Wang YH, Chen J, Lu CM. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 2014;14:64. [PMID: 25099181 DOI: 10.1186/1472-6823-14-64] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 395 |
Dedov II, Melnichenko GA, Krivko AA, Kuznetsov NS, Troshina EA. Carbohydrate metabolism and quality of life in patients after surgical treatment of insulinoma. Obes metabol 2014;11:18-22. [DOI: 10.14341/omet2014318-22] [Reference Citation Analysis]
|
| 396 |
Rossi S, Viera FT, Ghittoni G, Cobianchi L, Rosa LL, Siciliani L, Bortolotto C, Veronese L, Vercelli A, Gallotti A, Ravetta V. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas 2014;43:938-45. [PMID: 24717825 DOI: 10.1097/MPA.0000000000000133] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 397 |
Jiang J, Zhang L, Wu Z, Ai Z, Hou Y, Lu Z, Gao X. A rare case of watery diarrhea, hypokalemia and achlorhydria syndrome caused by pheochromocytoma. BMC Cancer. 2014;14:553. [PMID: 25081061 DOI: 10.1186/1471-2407-14-553] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 398 |
Igor V. Maev, Dmitry N. Andreev, Yuriy A. Kucheryavyy, Diana T. Dicheva. Neuroendocrine Tumors of the Pancreas: Molecular Pathogenesis and Perspectives on Targeted Therapies. J Can Res Updates 2014;3. [DOI: 10.6000/1929-2279.2014.03.03.4] [Reference Citation Analysis]
|
| 399 |
Luo Y, Dong Z, Chen J, Chan T, Lin Y, Chen M, Li ZP, Feng ST. Pancreatic neuroendocrine tumours: correlation between MSCT features and pathological classification. Eur Radiol 2014;24:2945-52. [PMID: 25048189 DOI: 10.1007/s00330-014-3317-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 400 |
Zhang X, Ma L, Bao H, Zhang J, Wang Z, Gong P. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study. BMC Endocr Disord. 2014;14:54. [PMID: 25001493 DOI: 10.1186/1472-6823-14-54] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 401 |
Mohammad Alizadeh AH, Parhizkar B, Rajabalinia H. The value of endoscopic ultrasound in a 47-year-old man with cystic lesions of the liver and pancreas. Case Rep Gastroenterol 2014;8:141-7. [PMID: 24847197 DOI: 10.1159/000362439] [Reference Citation Analysis]
|
| 402 |
Han X, Xu X, Jin D, Wang D, Ji Y, Lou W. Clinicopathological characteristics and prognosis-related factors of resectable pancreatic neuroendocrine tumors: a retrospective study of 104 cases in a single Chinese center. Pancreas 2014;43:526-31. [PMID: 24658317 DOI: 10.1097/MPA.0000000000000065] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 403 |
Kuo JH, Lee JA, Chabot JA. Nonfunctional pancreatic neuroendocrine tumors. Surg Clin North Am. 2014;94:689-708. [PMID: 24857584 DOI: 10.1016/j.suc.2014.02.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 404 |
Valle JW, Eatock M, Clueit B, Gabriel Z, Ferdinand R, Mitchell S. A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. Cancer Treatment Reviews 2014;40:376-89. [DOI: 10.1016/j.ctrv.2013.08.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 405 |
Meeker A, Heaphy C. Gastroenteropancreatic endocrine tumors. Molecular and Cellular Endocrinology 2014;386:101-20. [DOI: 10.1016/j.mce.2013.07.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 406 |
Krampitz GW. WITHDRAWN: In Brief. Current Problems in Surgery 2014. [DOI: 10.1067/j.cpsurg.2014.02.002] [Reference Citation Analysis]
|
| 407 |
Krampitz GW, Norton JA. WITHDRAWN: Current Problems in Surgery: Pancreatic Neuroendocrine Tumors. Current Problems in Surgery 2014. [DOI: 10.1067/j.cpsurg.2013.12.002] [Reference Citation Analysis]
|
| 408 |
Sadowski SM, Weisbrod AB, Ellis R, Patel D, Alimchandani M, Quezado M, Millo C, Venzon DJ, Nilubol N, Linehan WM, Kebebew E. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions. J Am Coll Surg 2014;218:997-1003. [PMID: 24661849 DOI: 10.1016/j.jamcollsurg.2014.01.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 409 |
Krampitz GW, Norton JA. Pancreatic neuroendocrine tumors. Curr Probl Surg. 2013;50:509-545. [PMID: 24206780 DOI: 10.1067/j.cpsurg.2013.08.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 410 |
Öberg KE. Management of neuroendocrine tumors: current and future therapies. Expert Review of Endocrinology & Metabolism 2014;6:49-62. [DOI: 10.1586/eem.10.81] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 411 |
Haynes A. Neuroendocrine tumors of the pancreas. Complex General Surgical Oncology: A Case-Based Approach - Volume 2 2014. [DOI: 10.2217/ebo.13.90] [Reference Citation Analysis]
|
| 412 |
Attili F, Capurso G, Vanella G, Fuccio L, Delle Fave G, Costamagna G, Larghi A. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. Dig Liver Dis 2014;46:9-17. [PMID: 23731843 DOI: 10.1016/j.dld.2013.04.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 413 |
Haslerud T. SPECT/CT in Neuroendrocrine Tumours. Clinical Applications of SPECT-CT 2014. [DOI: 10.1007/978-3-642-35283-6_5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 414 |
Tang S, Wu R, Bhaijee F. Zollinger–Ellison Syndrome. Video Journal and Encyclopedia of GI Endoscopy 2014;1:666-668. [DOI: 10.1016/j.vjgien.2013.06.005] [Reference Citation Analysis]
|
| 415 |
Sakamoto Y, Sakata K, Nakagawa S, Hashimoto D, Ikuta Y, Chikamoto A, Watanabe M, Beppu T, Baba H. A minute nonfunctioning pancreatic neuroendocrine tumor with lymph node metastasis. Int Canc Conf J 2014;3:16-18. [DOI: 10.1007/s13691-013-0107-9] [Reference Citation Analysis]
|
| 416 |
Djukom C, Porro LJ, Mrazek A, Townsend CM Jr, Hellmich MR, Chao C. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression. Pancreas 2014;43:88-92. [PMID: 24263107 DOI: 10.1097/MPA.0b013e3182a44ab4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 417 |
Nasir A, Strosberg JR, Kvols LK, Muhammad J, Nasir NA, Mills O, Coppola D. Molecular Pathology and Diagnostics of Pancreatic Endocrine Neoplasms. Molecular Pathology and Diagnostics of Cancer 2014. [DOI: 10.1007/978-94-007-7192-5_14] [Reference Citation Analysis]
|
| 418 |
Waguespack SG, Ying AK. Pheochromocytoma and multiple endocrine neoplasia syndromes. Pediatric Endocrinology 2014. [DOI: 10.1016/b978-1-4557-4858-7.00023-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 419 |
Epelboym I, Mazeh H. Zollinger-Ellison syndrome: Classical considerations and current controversies. Oncologist. 2014;19:44-50. [PMID: 24319020 DOI: 10.1634/theoncologist.2013-0369] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 420 |
Zerbi A, Capitanio V, Boninsegna L, Delle Fave G, Pasquali C, Rindi G, Campana D, Falconi M; AISP-Network Study Group. Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB (Oxford) 2013;15:935-43. [PMID: 23472667 DOI: 10.1111/hpb.12065] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 421 |
Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, Watson R, Tomlinson JS, Hines OJ, Reber HA, Donahue TR. Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival. J Gastrointest Surg 2013;17:2105-13. [PMID: 24101447 DOI: 10.1007/s11605-013-2360-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 422 |
Pinato DJ, Tan TM, Toussi ST, Ramachandran R, Martin N, Meeran K, Ngo N, Dina R, Sharma R. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer 2014;110:115-22. [PMID: 24231952 DOI: 10.1038/bjc.2013.682] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 423 |
Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol 2013;29:650-61. [PMID: 24100728 DOI: 10.1097/MOG.0b013e328365efb1] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 424 |
Hamze Z, Vercherat C, Bernigaud-Lacheretz A, Bazzi W, Bonnavion R, Lu J, Calender A, Pouponnot C, Bertolino P, Roche C. Altered MENIN expression disrupts the MAFA differentiation pathway in insulinoma. Endocr Relat Cancer. 2013;20:833-848. [PMID: 24157940 DOI: 10.1530/ERC-13-0164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 425 |
Saupe F, Schwenzer A, Jia Y, Gasser I, Spenlé C, Langlois B, Kammerer M, Lefebvre O, Hlushchuk R, Rupp T. Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. Cell Rep. 2013;5:482-492. [PMID: 24139798 DOI: 10.1016/j.celrep.2013.09.014] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 426 |
Balachandran A, Tamm EP, Bhosale PR, Patnana M, Vikram R, Fleming JB, Katz MH, Charnsangavej C. Pancreatic neuroendocrine neoplasms: diagnosis and management. Abdom Imaging. 2013;38:342-357. [PMID: 22707246 DOI: 10.1007/s00261-012-9923-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 427 |
Vinik AI, Raymond E. Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib. Therap Adv Gastroenterol 2013;6:396-411. [PMID: 24003340 DOI: 10.1177/1756283X13493878] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 428 |
Morin E, Cheng S, Mete O, Serra S, Araujo PB, Temple S, Cleary S, Gallinger S, Greig PD, McGilvray I, Wei A, Asa SL, Ezzat S. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior. Cancer Med. 2013;2:701-711. [PMID: 24403235 DOI: 10.1002/cam4.96] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 429 |
Díaz Pérez JÁ, Currás Freixes M. Chromogranin A and neuroendocrine tumors. Endocrinología y Nutrición (English Edition) 2013;60:386-395. [DOI: 10.1016/j.endoen.2012.10.007] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 430 |
Babu V, Paul N, Yu R. Animal models and cell lines of pancreatic neuroendocrine tumors. Pancreas 2013;42:912-23. [PMID: 23851429 DOI: 10.1097/MPA.0b013e31827ae993] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 431 |
Choi YH, Han HS, Lim SN, Lee SY, Koo JH, Lee OJ, Lee KH, Kim ST. Multiple cardiac metastases from a nonfunctioning pancreatic neuroendocrine tumor. Cancer Res Treat 2013;45:150-4. [PMID: 23864849 DOI: 10.4143/crt.2013.45.2.150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 432 |
Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013;92:135-81. [PMID: 23645327 DOI: 10.1097/MD.0b013e3182954af1] [Cited by in Crossref: 138] [Cited by in F6Publishing: 148] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 433 |
Sadaria MR, Hruban RH, Edil BH. Advancements in pancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2013;7:477-90. [PMID: 23899286 DOI: 10.1586/17474124.2013.811058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 434 |
Weber HC. Medical treatment of neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2013;20:27-31. [PMID: 23221494 DOI: 10.1097/MED.0b013e32835c034f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 435 |
Young HTM, Carr NJ, Green B, Tilley C, Bhargava V, Pearce N. Accuracy of visual assessments of proliferation indices in gastroenteropancreatic neuroendocrine tumours. J Clin Pathol 2013;66:700-4. [DOI: 10.1136/jclinpath-2012-201217] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 436 |
Rufini V, Baum RP, Castaldi P, Treglia G, De Gaetano AM, Carreras C, Kaemmerer D, Hommann M, Hörsch D, Bonomo L. Role of PET/CT in the functional imaging of endocrine pancreatic tumors. Abdom Imaging. 2012;37:1004-1020. [PMID: 22422069 DOI: 10.1007/s00261-012-9871-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 437 |
Han X, Ji Y, Zhao J, Xu X, Lou W. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors. Tumor Biol 2013;34:2871-9. [DOI: 10.1007/s13277-013-0849-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 438 |
Anthony LB. Practical guide to supportive care of patients with functional neuroendocrine tumors. Semin Oncol. 2013;40:45-55. [PMID: 23391112 DOI: 10.1053/j.seminoncol.2012.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 439 |
Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013;40:56-68. [PMID: 23391113 DOI: 10.1053/j.seminoncol.2012.11.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 440 |
Kawamoto S, Johnson PT, Shi C, Singhi AD, Hruban RH, Wolfgang CL, Edil BH, Fishman EK. Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT. AJR Am J Roentgenol. 2013;200:W283-W290. [PMID: 23436873 DOI: 10.2214/ajr.12.8941] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 441 |
Dickson PV, Behrman SW. Management of pancreatic neuroendocrine tumors. Surg Clin North Am. 2013;93:675-691. [PMID: 23632152 DOI: 10.1016/j.suc.2013.02.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 442 |
Gilbert JA, Adhikari LJ, Lloyd RV, Halfdanarson TR, Muders MH, Ames MM. Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas 2013;42:411-21. [PMID: 23211371 DOI: 10.1097/MPA.0b013e31826cb243] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 443 |
Ma DW, Kim MK, Yoon SO, Rhee K, Yoon DS, Park H. [A case of double primary neuroendocrine tumor from duodenum and pancreas]. Korean J Gastroenterol 2013;61:155-9. [PMID: 23575234 DOI: 10.4166/kjg.2013.61.3.155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 444 |
Lopez CL, Falconi M, Waldmann J, Boninsegna L, Fendrich V, Goretzki PK, Langer P, Kann PH, Partelli S, Bartsch DK. Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. Ann Surg. 2013;257:308-314. [PMID: 22580937 DOI: 10.1097/sla.0b013e3182536339] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 445 |
Bausch D, Keck T. Chirurgie endokriner Tumoren des Pankreas. Onkologe 2013;19:224-229. [DOI: 10.1007/s00761-012-2394-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 446 |
Wolin EM. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett. 2013;335:1-8. [PMID: 23419523 DOI: 10.1016/j.canlet.2013.02.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 447 |
Phan AT. Metastatic pancreatic neuroendocrine tumors (pNET): Placing current findings into perspective. Cancer Treatment Reviews 2013;39:3-9. [DOI: 10.1016/j.ctrv.2012.02.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 448 |
Ito T, Igarashi H, Uehara H, Jensen RT. Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother 2013;14:307-21. [PMID: 23363383 DOI: 10.1517/14656566.2013.767332] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 449 |
Louda F, Chadli A, Elaziz S, Elghomari H, Farouqi A. Malignant insulinoma misdiagnosed and treated as epilepsy. Ann Endocrinol (Paris) 2013;74:53-5. [PMID: 23351560 DOI: 10.1016/j.ando.2012.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 450 |
Oh TG, Chung MJ, Park JY, Bang SM, Park SW, Chung JB, Song SY. Prognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experience. Yonsei Med J 2012;53:944-51. [PMID: 22869477 DOI: 10.3349/ymj.2012.53.5.944] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 451 |
Yuzawa H, Himan T, Umegae S. A Case of Laparoscopic Distal Pancreatectomy for a Cystic Changed Endocrine Tumor. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2013;74:2896-2900. [DOI: 10.3919/jjsa.74.2896] [Reference Citation Analysis]
|
| 452 |
Musholt TJ. Seltene hormonaktive Tumoren des Pankreas – chirurgische Therapie. Erkrankungen des Pankreas 2013. [DOI: 10.1007/978-3-642-37964-2_46] [Reference Citation Analysis]
|
| 453 |
Doi R, Abe Y, Nakamura N, Ito T, Yogo A, Matsubayashi J, Kito Y, Ura K, Toyoda E, Taira K, Oe H, Kawashima K, Ishigami S. Surgical treatment of pancreatic neuroendocrine tumors. Journal of the Japan Pancreas Society 2013;28:699-706. [DOI: 10.2958/suizo.28.699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 454 |
Shrikhande SV, Sirohi B, Goel M, Barreto SG. Pancreatic neuroendocrine tumors. Indian J Gastroenterol 2013;32:3-17. [PMID: 23054950 DOI: 10.1007/s12664-012-0257-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 455 |
Igarashi H, Lee L, Niina Y, Hijioka M, Tachibana Y, Ueda K, Fujiyama T, Miki M, Ito T. Diagnosis of pancreatic neuroendocrine tumors. Journal of the Japan Pancreas Society 2013;28:691-698. [DOI: 10.2958/suizo.28.691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 456 |
Almohareb O, Rivera J. A Case of Ectopic Growth Hormone Releasing Hormone (GHRH) from Pancreatic Neuroendocrine Tumor Resistant to Therapy. OJEMD 2013;03:271-275. [DOI: 10.4236/ojemd.2013.37037] [Reference Citation Analysis]
|
| 457 |
Ynson ML. Glucagonoma: Gastrointestinal Features. Atlas of Dermatological Manifestations of Gastrointestinal Disease 2013. [DOI: 10.1007/978-1-4614-6191-3_55] [Reference Citation Analysis]
|
| 458 |
Arnold R, Langer P, Rothmund M, Klöppel G, Kann P, Heverhagen J, Fendrich V, Bartsch D, Rinke A, Müller X, Klose K, Brenner W, Prasad V, Wiedenmann B, Jann H, Gress T, Pascher A, Neuhaus P, Habbe N, Simon B, Stinner B. Endokrine Tumoren des gastroenteropankreatischen Systems. Praxis der Viszeralchirurgie 2013. [DOI: 10.1007/978-3-642-14285-7_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 459 |
Varshney R, Hazari PP, Fernandez P, Schulz J, Allard M, Mishra AK. 68Ga-Labeled Bombesin Analogs for Receptor-Mediated Imaging. Recent Results in Cancer Research 2013. [DOI: 10.1007/978-3-642-27994-2_12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 460 |
Muniraj T, Vignesh S, Shetty S, Thiruvengadam S, Aslanian HR. Pancreatic neuroendocrine tumors. Disease-a-Month 2013;59:5-19. [DOI: 10.1016/j.disamonth.2012.10.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 461 |
Langer P, Fendrich V. Hormoninaktive endokrine Tumoren des Pankreas – chirurgische Therapie. Erkrankungen des Pankreas 2013. [DOI: 10.1007/978-3-642-37964-2_45] [Reference Citation Analysis]
|
| 462 |
Davì MV, Toaiari M, Francia G. Epidemiology and Clinical Presentation. Uncommon Pancreatic Neoplasms 2013. [DOI: 10.1007/978-88-470-2673-5_7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 463 |
Benslama N, Lombard-bohas C, Walter T. Traitement des tumeurs neuroendocrines digestives par les inhibiteurs de mTOR : les prémices d’un traitement personnalisé. Médecine personnalisée en cancérologie digestive 2013. [DOI: 10.1007/978-2-8178-0527-6_22] [Reference Citation Analysis]
|
| 464 |
Fendrich V, Maschuw K, Rehm J, Buchholz M, Holler JP, Slater EP, Bartsch DK, Waldmann J. Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors. ScientificWorldJournal 2012;2012:529151. [PMID: 23346016 DOI: 10.1100/2012/529151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 465 |
Díaz Pérez JÁ, Currás Freixes M. [Chromogranin A and neuroendocrine tumors]. Endocrinol Nutr 2013;60:386-95. [PMID: 23271036 DOI: 10.1016/j.endonu.2012.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 466 |
Crabtree KL, Anderson KK, Haynes NG, Arnold PM. Surgical treatment of multiple spine metastases from gastrinoma. Evid Based Spine Care J 2011;2:45-50. [PMID: 23230405 DOI: 10.1055/s-0031-1274756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 467 |
Ogawa M, Kawaguchi Y, Maruno A, Ito H, Nakagohri T, Hirabayashi K, Yamamuro H, Yamashita T, Mine T. Small serotonin-positive pancreatic endocrine tumors caused obstruction of the main pancreatic duct. World J Gastroenterol 2012; 18(45): 6669-6673 [PMID: 23236243 DOI: 10.3748/wjg.v18.i45.6669] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 468 |
Di Florio A, Sancho V, Moreno P, Delle Fave G, Jensen RT. Gastrointestinal hormones stimulate growth of Foregut Neuroendocrine Tumors by transactivating the EGF receptor. Biochim Biophys Acta 2013;1833:573-82. [PMID: 23220008 DOI: 10.1016/j.bbamcr.2012.11.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 469 |
Krampitz GW, Norton JA, Poultsides GA, Visser BC, Sun L, Jensen RT. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg. 2012;147:820-827. [PMID: 22987171 DOI: 10.1001/archsurg.2012.1261] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 470 |
Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol 2012;26:791-802. [PMID: 23582919 DOI: 10.1016/j.bpg.2012.12.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 471 |
Capelli P, Fassan M, Scarpa A. Pathology - grading and staging of GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:705-17. [PMID: 23582914 DOI: 10.1016/j.bpg.2013.01.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 472 |
Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol 2012;26:737-53. [PMID: 23582916 DOI: 10.1016/j.bpg.2012.12.003] [Cited by in Crossref: 145] [Cited by in F6Publishing: 156] [Article Influence: 13.2] [Reference Citation Analysis]
|
| 473 |
Gupta RA, Udwadia FE, Agrawal P, Doctor N. Pancreatic glucagonoma with pancreatic calcification. Pancreatology 2013;13:327-9. [PMID: 23719610 DOI: 10.1016/j.pan.2012.11.308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 474 |
Wiedmann MW, Mössner J. Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors. Clin Med Insights Oncol 2012;6:381-93. [PMID: 23226079 DOI: 10.4137/CMO.S7350] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 475 |
Amador Cano A, García F, Espinoza A, Bezies N, Herrera E, De Leija Portilla J. Nonfunctional neuroendocrine tumor of the pancreas: Case report and review of the literature. Int J Surg Case Rep 2013;4:225-8. [PMID: 23287065 DOI: 10.1016/j.ijscr.2012.10.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 476 |
Tomassetti P, Cevenini M, Guidetti E, Cacciari G, Cipollini ML, Galassi E, Fabbri MC, Nori F, Campana D, Corinaldesi R, De Giorgio R. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors. Clinical Investigation 2012;2:1123-1131. [DOI: 10.4155/cli.12.111] [Reference Citation Analysis]
|
| 477 |
Cherif R, Gaujoux S, Couvelard A, Dokmak S, Vuillerme MP, Ruszniewski P, Belghiti J, Sauvanet A. Parenchyma-sparing resections for pancreatic neuroendocrine tumors. J Gastrointest Surg 2012;16:2045-55. [PMID: 22911124 DOI: 10.1007/s11605-012-2002-7] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 7.4] [Reference Citation Analysis]
|
| 478 |
Ito T, Cadiot G, Jensen RT. Diagnosis of Zollinger-Ellison syndrome: Increasingly difficult. World J Gastroenterol 2012; 18(39): 5495-5503 [PMID: 23112541 DOI: 10.3748/wjg.v18.i39.5495] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 479 |
Hanazaki K, Sakurai A, Munekage M, Ichikawa K, Namikawa T, Okabayashi T, Imamura M. Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. Surg Today. 2013;43:229-236. [PMID: 23076685 DOI: 10.1007/s00595-012-0376-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 480 |
Rustagi T, Rai M, Bauer F. Non-functional Pancreatic Neuroendocrine Tumor as an Incidentaloma—A Case Report and Review of Literature. J Gastrointest Canc 2013;44:336-42. [DOI: 10.1007/s12029-012-9445-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 481 |
Walls GV, Reed AA, Jeyabalan J, Javid M, Hill NR, Harding B, Thakker RV. Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors. Endocrinology 2012;153:5167-79. [PMID: 23024266 DOI: 10.1210/en.2012-1675] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 482 |
Frilling A, Akerström G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012;19:R163-R185. [PMID: 22645227 DOI: 10.1530/erc-12-0024] [Cited by in Crossref: 99] [Cited by in F6Publishing: 109] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 483 |
Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol 2012;47:941-60. [PMID: 22886480 DOI: 10.1007/s00535-012-0642-8] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 484 |
Larghi A, Capurso G, Carnuccio A, Ricci R, Alfieri S, Galasso D, Lugli F, Bianchi A, Panzuto F, De Marinis L, Falconi M, Delle Fave G, Doglietto GB, Costamagna G, Rindi G. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. Gastrointest Endosc 2012;76:570-7. [PMID: 22898415 DOI: 10.1016/j.gie.2012.04.477] [Cited by in Crossref: 118] [Cited by in F6Publishing: 127] [Article Influence: 10.7] [Reference Citation Analysis]
|
| 485 |
Feldmann G, Bisht S, Schütte U, Haarmann J, Brossart P. Everolimus for the treatment of pancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy 2012;13:2073-84. [DOI: 10.1517/14656566.2012.713348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 486 |
Basu S. Developing a unified imaging approach for neuroendocrine tumours with the evolution of PET-CT with ⁶⁸Ga-labelled somatostatin analogues: could this be tailored according to specific clinical context and individual patient requirement? Nucl Med Commun 2012;33:1007-10. [PMID: 22850607 DOI: 10.1097/MNM.0b013e32835710a3] [Reference Citation Analysis]
|
| 487 |
Capurso G, Festa S, Valente R, Piciucchi M, Panzuto F, Jensen RT, Delle Fave G. Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol 2012;49:R37-50. [PMID: 22586144 DOI: 10.1530/JME-12-0069] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 488 |
Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, Takahata S, Nakamura M, Ito T, Tanaka M. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol 2012;47:678-85. [PMID: 22350698 DOI: 10.1007/s00535-012-0540-0] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 489 |
Moncayo VM, Martin DR, Sarmiento JM, Zbytek B, Fox T, Schuster DM. ¹¹¹In OctreoScan SPECT-MRI fusion for the detection of a pancreatic insulinoma. Clin Nucl Med 2012;37:e53-6. [PMID: 22310271 DOI: 10.1097/RLU.0b013e31823ea402] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 490 |
Jensen RT. Pancreatic Endocrine Tumors. Textbook of Clinical Gastroenterology and Hepatology 2012. [DOI: 10.1002/9781118321386.ch112] [Reference Citation Analysis]
|
| 491 |
Tejedor Bravo M, Justo LM, Lasala JP, Moreira Vicente VF, Ruiz AC, Scapa Mde L. Acute pancreatitis secondary to neuroendocrine pancreatic tumors: report of 3 cases and literature review. Pancreas 2012;41:485-9. [PMID: 22415668 DOI: 10.1097/MPA.0b013e318227adef] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 492 |
Megibow AJ. Unusual solid pancreatic tumors. Radiol Clin North Am 2012;50:499-513. [PMID: 22560694 DOI: 10.1016/j.rcl.2012.03.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 493 |
Fendrich V, Maschuw K, Waldmann J, Buchholz M, Rehm J, Gress TM, Bartsch DK, König A. Epithelial-mesenchymal transition is a critical step in tumorgenesis of pancreatic neuroendocrine tumors. Cancers (Basel). 2012;4:281-294. [PMID: 24213240 DOI: 10.3390/cancers4010281] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 494 |
Riccardi F, Rizzo M, Festino L, Ambrosio F, Molino C, Uomo G, Cartenì G. Therapy innovation for the treatment of pancreatic neuroendocrine tumors. Expert Opin Ther Targets 2012;16 Suppl 2:S91-102. [PMID: 22372544 DOI: 10.1517/14728222.2012.665880] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 495 |
Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98-119. [PMID: 22261919 DOI: 10.1159/000335591] [Cited by in Crossref: 374] [Cited by in F6Publishing: 408] [Article Influence: 34.0] [Reference Citation Analysis]
|
| 496 |
Minter RM, Simeone DM. Contemporary management of nonfunctioning pancreatic neuroendocrine tumors. J Gastrointest Surg 2012;16:435-46. [PMID: 22009463 DOI: 10.1007/s11605-011-1693-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 497 |
Metz DC. Diagnosis of the Zollinger–Ellison syndrome. Clin Gastroenterol Hepatol 2012;10:126-30. [PMID: 21806955 DOI: 10.1016/j.cgh.2011.07.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 498 |
Zárate X, Williams N, Herrera MF. Pancreatic incidentalomas. Best Practice & Research Clinical Endocrinology & Metabolism 2012;26:97-103. [DOI: 10.1016/j.beem.2011.06.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 499 |
Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol. 2012;24:46-55. [PMID: 22080942 DOI: 10.1097/cco.0b013e32834c554d] [Cited by in Crossref: 78] [Cited by in F6Publishing: 68] [Article Influence: 7.1] [Reference Citation Analysis]
|
| 500 |
Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol 2012;10:199-202. [PMID: 21871248 DOI: 10.1016/j.cgh.2011.08.012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 501 |
Newey PJ, Thakker RV. Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. Endocr Pract. 2011;17 Suppl 3:8-17. [PMID: 21454234 DOI: 10.4158/ep10379.ra] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 502 |
Fendrich V, Wiese D, Waldmann J, Lauth M, Heverhagen AE, Rehm J, Bartsch DK. Hedgehog inhibition with the orally bioavailable Smo antagonist LDE225 represses tumor growth and prolongs survival in a transgenic mouse model of islet cell neoplasms. Ann Surg. 2011;254:818-823; discussion 823. [PMID: 22042473 DOI: 10.1097/sla.0b013e318236bc0f] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 503 |
Niina Y, Fujimori N, Nakamura T, Igarashi H, Oono T, Nakamura K, Kato M, Jensen RT, Ito T, Takayanagi R. The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. Gut Liver 2012;6:287-94. [PMID: 22844555 DOI: 10.5009/gnl.2012.6.3.287] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 504 |
Philips S, Shah SN, Vikram R, Verma S, Shanbhogue AK, Prasad SR. Pancreatic endocrine neoplasms: a current update on genetics and imaging. Br J Radiol 2012;85:682-96. [PMID: 22253347 DOI: 10.1259/bjr/85014761] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 505 |
Oberstein PE, Saif MW. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 2012;6:41-51. [PMID: 22253554 DOI: 10.4137/CMO.S7319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 506 |
Balachandran A, Fleming JB, Callender GG, Krishnan S, Yao JC. Pancreatic Neuroendocrine Tumors. Oncologic Imaging: A Multidisciplinary Approach 2012. [DOI: 10.1016/b978-1-4377-2232-1.00013-9] [Reference Citation Analysis]
|
| 507 |
Jensen RT. Pancreatic Endocrine Tumors. Goldman's Cecil Medicine 2012. [DOI: 10.1016/b978-1-4377-1604-7.00201-3] [Reference Citation Analysis]
|
| 508 |
Popescu A, Ciocalteu AM, Gheonea DI, Iordache S, Popescu CF, Saftoiu A, Ciurea T. Utility of endoscopic ultrasound multimodal examination with fine needle aspiration for the diagnosis of pancreatic insulinoma - a case report. Curr Health Sci J 2012;38:36-40. [PMID: 24778840] [Reference Citation Analysis]
|
| 509 |
Díaz Díaz D, Ibarrola C, Goméz Sanz R, Pérez Hurtado B, Salazar Tabares J, Colina Ruizdelgado F. Neuroendocrine tumor of the pancreas in a patient with tuberous sclerosis: a case report and review of the literature. Int J Surg Pathol 2012;20:390-5. [PMID: 22169969 DOI: 10.1177/1066896911428735] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 510 |
Wolinsky JP. Commentary. Evid Based Spine Care J 2011;2:50. [PMID: 23230406 DOI: 10.1055/s-0032-1330857] [Reference Citation Analysis]
|
| 511 |
Öberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21 Suppl 7:vii72-vii80. [PMID: 20943646 DOI: 10.1093/annonc/mdq290] [Cited by in Crossref: 69] [Cited by in F6Publishing: 83] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 512 |
Feliberti E, Perry R, Vinik A. Advances in the management and treatment of gastroenteropancreatic neuroendocrine tumors. Clinical Investigation 2011;1:1455-1468. [DOI: 10.4155/cli.11.120] [Reference Citation Analysis]
|
| 513 |
Rossella B, Massimo F. Surgical approach. Advances in Neuroendocrine Tumor Management 2011. [DOI: 10.2217/ebo.11.9] [Reference Citation Analysis]
|
| 514 |
Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 2011;18:S17-25. [DOI: 10.1530/erc-10-0280] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 515 |
Baltogiannis G, Katsios C, Roukos DH. New target therapies for patients with neuroendocrine tumors of the pancreas. Expert Rev Gastroenterol Hepatol 2011;5:563-6. [PMID: 21910571 DOI: 10.1586/egh.11.55] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 516 |
Goldstein R, Meyer T. Role of everolimus in pancreatic neuroendocrine tumors. Expert Rev Anticancer Ther. 2011;11:1653-1665. [PMID: 21932937 DOI: 10.1586/era.11.145] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 517 |
Shiokawa M, Kodama Y, Hiramatsu Y, Kurita A, Sawai Y, Uza N, Watanabe T, Chiba T. Autoimmune pancreatitis exhibiting multiple mass lesions. Case Rep Gastroenterol. 2011;5:528-533. [PMID: 22087084 DOI: 10.1159/000331799] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 518 |
Oberg KE. The management of neuroendocrine tumours: current and future medical therapy options. Clin Oncol (R Coll Radiol). 2012;24:282-293. [PMID: 21907552 DOI: 10.1016/j.clon.2011.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 519 |
Liakakos T, Roukos DH. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors. Future Oncology 2011;7:1025-9. [DOI: 10.2217/fon.11.88] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 520 |
Wiedenmann B, Pavel M, Kos-Kudla B. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors. Neuroendocrinology 2011;94:177-90. [PMID: 21893937 DOI: 10.1159/000329386] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 521 |
Di Florio A, Adesso L, Pedrotti S, Capurso G, Pilozzi E, Corbo V, Scarpa A, Geremia R, Delle Fave G, Sette C. Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells. Endocr Relat Cancer 2011;18:541-54. [PMID: 21712346 DOI: 10.1530/ERC-10-0153] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 522 |
Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT. Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection. Arch Surg. 2011;146:724-732. [PMID: 21690450 DOI: 10.1001/archsurg.2011.129] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 523 |
Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011;4:29. [PMID: 21672194 DOI: 10.1186/1756-8722-4-29] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 524 |
Vinik AI, Gonzales MR. New and emerging syndromes due to neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:19-63, vii. [PMID: 21349410 DOI: 10.1016/j.ecl.2010.12.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 525 |
Jensen RT. Cancer: a roadmap for the land of small tumors. Nat Rev Endocrinol 2011;7:319-21. [PMID: 21556022 DOI: 10.1038/nrendo.2011.73] [Reference Citation Analysis]
|
| 526 |
Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372-2377. [PMID: 21555696 DOI: 10.1200/jco.2010.33.0688] [Cited by in Crossref: 214] [Cited by in F6Publishing: 226] [Article Influence: 17.8] [Reference Citation Analysis]
|
| 527 |
Rehfeld JF, Gingras MH, Bardram L, Hilsted L, Goetze JP, Poitras P. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011;140:1444-53. [PMID: 21315717 DOI: 10.1053/j.gastro.2011.01.051] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 6.1] [Reference Citation Analysis]
|
| 528 |
Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr Res. 2011;36:35-43. [PMID: 21226566 DOI: 10.3109/07435800.2010.525085] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 529 |
Fendrich V, Rehm J, Waldmann J, Buchholz M, Christofori G, Lauth M, Slater EP, Bartsch DK. Hedgehog inhibition with cyclopamine represses tumor growth and prolongs survival in a transgenic mouse model of islet cell tumors. Ann Surg. 2011;253:546-552. [PMID: 21239987 DOI: 10.1097/SLA.0b013e31820a5bbe] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 530 |
Tóth M, Szücs N, Jakab Z, Doros A, Nemes Z, Rácz K. [Malignant insulinoma]. Orv Hetil 2011;152:398-402. [PMID: 21354956 DOI: 10.1556/OH.2011.29058] [Reference Citation Analysis]
|
| 531 |
Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12:448-457. [PMID: 20882439 DOI: 10.1007/s11894-010-0141-0] [Cited by in Crossref: 189] [Cited by in F6Publishing: 137] [Article Influence: 15.8] [Reference Citation Analysis]
|
| 532 |
Schneider R, Waldmann J, Swaid Z, Ramaswamy A, Fendrich V, Bartsch DK, Schlosser K. Calcitonin-secreting pancreatic endocrine tumors: systematic analysis of a rare tumor entity. Pancreas 2011;40:213-21. [PMID: 21178652 DOI: 10.1097/MPA.0b013e3182015f5d] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 533 |
Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi M. Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology. 2011;93:223-229. [PMID: 21358176 DOI: 10.1159/000324770] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 534 |
Fendrich V, Bartsch DK. Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg. 2011;396:299-311. [PMID: 21279821 DOI: 10.1007/s00423-011-0741-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 535 |
Oberg K. Pancreatic endocrine tumors. Semin Oncol. 2010;37:594-618. [PMID: 21167379 DOI: 10.1053/j.seminoncol.2010.10.014] [Cited by in Crossref: 127] [Cited by in F6Publishing: 135] [Article Influence: 10.6] [Reference Citation Analysis]
|
| 536 |
Kuiper P, Hawinkels LJ, Jonge-Muller ES, Biemond I, Lamers CB, Verspaget HW. Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2011; 17(2): 219-225 [PMID: 21245995 DOI: 10.3748/wjg.v17.i2.219] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 537 |
Langer P, Bartsch DK. Endokrine Chirurgie des Bauchraums. Behandlungsfehler und Haftpfl icht in der Viszeralchirurgie 2011. [DOI: 10.1007/978-3-642-05372-6_24] [Reference Citation Analysis]
|
| 538 |
Landry CS, Rich T, Jimenez C, Grubbs EG, Lee JE, Perrier ND. Multiple Endocrine Neoplasia. Neuroendocrine Tumors 2011. [DOI: 10.1007/978-1-60327-997-0_3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 539 |
Edwards CM, Smith JJ, Merchant NB, Parikh AA. Targeting Angiogenesis in the Treatment of Hepatic Metastasis. Liver Metastasis: Biology and Clinical Management 2011. [DOI: 10.1007/978-94-007-0292-9_15] [Reference Citation Analysis]
|
| 540 |
Willet S, Wright C. Pancreatic Plasticity and Reprogramming: Novel Directions Towards Disease Therapy. Nuclear Reprogramming and Stem Cells 2011. [DOI: 10.1007/978-1-61779-225-0_15] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 541 |
Verbeke CS. Endocrine tumours of the pancreas. Histopathology 2010;56:669-82. [PMID: 20546332 DOI: 10.1111/j.1365-2559.2010.03490.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 542 |
Luboldt W, Hartmann H, Wiedemann B, Zöphel K, Luboldt H. Gastroenteropancreatic Neuroendocrine Tumors: Standardizing Therapy Monitoring with 68 Ga-DOTATOC PET/CT Using the Example of Somatostatin Receptor Radionuclide Therapy. Mol Imaging 2010;9:7290.2010.00035. [DOI: 10.2310/7290.2010.00035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 543 |
Grande E, Díez JJ, Pachón V, Carrato A. Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). Clin Transl Oncol 2010;12:481-92. [PMID: 20615825 DOI: 10.1007/s12094-010-0541-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 544 |
Fendrich V, Michl P, Habbe N, Bartsch DK. Liver-specific therapies for metastases of neuroendocrine pancreatic tumors. World J Hepatol 2010; 2(10): 367-373 [PMID: 21160945 DOI: 10.4254/wjh.v2.i10.367] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 545 |
Casanovas MM. [Contributions of nuclear medicine to the diagnosis and follow-up of gastroenteropancreatic neuroendocrine tumors]. Endocrinol Nutr 2009;56 Suppl 3:14-9. [PMID: 20542215 DOI: 10.1016/S1575-0922(09)73505-3] [Reference Citation Analysis]
|
| 546 |
Massironi S, Conte D, Sciola V, Pirola L, Paggi S, Fraquelli M, Ciafardini C, Spampatti MP, Peracchi M. Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours. Dig Liver Dis 2010;42:635-41. [PMID: 20172770 DOI: 10.1016/j.dld.2010.01.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 547 |
Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT; North American Neuroendocrine Tumor Society (NANETS). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735-52. [PMID: 20664472 DOI: 10.1097/MPA.0b013e3181ebb168] [Cited by in Crossref: 387] [Cited by in F6Publishing: 386] [Article Influence: 29.8] [Reference Citation Analysis]
|
| 548 |
Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010;39:713-34. [PMID: 20664471 DOI: 10.1097/MPA.0b013e3181ebaffd] [Cited by in Crossref: 184] [Cited by in F6Publishing: 189] [Article Influence: 14.2] [Reference Citation Analysis]
|
| 549 |
Pomianowska E, Gladhaug IP, Grzyb K, Røsok BI, Edwin B, Bergestuen DS, Mathisen O. Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems. Scand J Gastroenterol 2010;45:971-9. [PMID: 20441530 DOI: 10.3109/00365521003782363] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 550 |
Zerbi A, Falconi M, Rindi G, Delle Fave G, Tomassetti P, Pasquali C, Capitanio V, Boninsegna L, Di Carlo V; AISP-Network Study Group. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol 2010;105:1421-9. [PMID: 20087335 DOI: 10.1038/ajg.2009.747] [Cited by in Crossref: 108] [Cited by in F6Publishing: 97] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 551 |
Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010;6:229-237. [PMID: 20146582 DOI: 10.2217/fon.09.165] [Cited by in Crossref: 70] [Cited by in F6Publishing: 79] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 552 |
Lu J, Herrera PL, Carreira C, Bonnavion R, Seigne C, Calender A, Bertolino P, Zhang CX. Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development. Gastroenterology 2010;138:1954-65. [PMID: 20138042 DOI: 10.1053/j.gastro.2010.01.046] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 7.9] [Reference Citation Analysis]
|
| 553 |
Osefo N, Ito T, Jensen RT. Gastric acid hypersecretory states: recent insights and advances. Curr Gastroenterol Rep 2009;11:433-41. [PMID: 19903418 DOI: 10.1007/s11894-009-0067-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 554 |
Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, Takano K, Obara T, Ishibashi M, Nakao K, Doi R, Shimatsu A, Nishida T, Komoto I, Hirata Y, Nakamura K, Igarashi H, Jensen RT, Wiedenmann B, Imamura M. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010;45:234-43. [PMID: 20058030 DOI: 10.1007/s00535-009-0194-8] [Cited by in Crossref: 281] [Cited by in F6Publishing: 301] [Article Influence: 21.6] [Reference Citation Analysis]
|
| 555 |
Akerström G, Hellman P. Surgical aspects of neuroendocrine tumours. Eur J Cancer 2009;45 Suppl 1:237-50. [PMID: 19775622 DOI: 10.1016/S0959-8049(09)70039-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 556 |
Jensen RT, Norton JA. Endocrine Tumors of the Pancreas and Gastrointestinal Tract. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2010. [DOI: 10.1016/b978-1-4160-6189-2.00032-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 557 |
Mills O, Nasir NA, Strosberg JR, Kvols LK, Coppola D, Nasir A. Recent Advances in the Pathogenesis of Pancreatic Endocrine Neoplasms. Mechanisms of Oncogenesis 2010. [DOI: 10.1007/978-90-481-3725-1_17] [Reference Citation Analysis]
|
| 558 |
Ekeblad S. Islet cell tumours. Adv Exp Med Biol 2010;654:771-89. [PMID: 20217524 DOI: 10.1007/978-90-481-3271-3_34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 559 |
Rohmer V. Actualités des tumeurs neuro endocrines : biologie moléculaire, imagerie et traitements ciblés. Bulletin de l'Académie Nationale de Médecine 2010;194:97-105. [DOI: 10.1016/s0001-4079(19)32365-9] [Reference Citation Analysis]
|
| 560 |
Schiller LR, Sellin JH. Diarrhea. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 211-232.e4. [DOI: 10.1016/b978-1-4160-6189-2.00015-9] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 561 |
Capurso G, Festa S, Piciucchi M, Valente R, Fave GD. Molecular Pathology of Pancreatic Endocrine Tumors. Pancreatic Cancer 2010. [DOI: 10.1007/978-0-387-77498-5_7] [Reference Citation Analysis]
|
| 562 |
Fendrich V, Bartsch D. Neuroendokrines Pankreaskarzinom. Praxis der Viszeralchirurgie Onkologische Chirurgie 2010. [DOI: 10.1007/978-3-642-03808-2_42] [Reference Citation Analysis]
|
| 563 |
Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am. 2009;89:1105-1121. [PMID: 19836487 DOI: 10.1016/j.suc.2009.06.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 4.6] [Reference Citation Analysis]
|
| 564 |
Capurso G, Falconi M, Panzuto F, Rinzivillo M, Boninsegna L, Bettini R, Corleto V, Borgia P, Pederzoli P, Scarpa A, Delle Fave G. Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. Am J Gastroenterol 2009;104:3034-41. [PMID: 19690522 DOI: 10.1038/ajg.2009.466] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 565 |
Figueiredo FA, Giovannini M, Monges G, Charfi S, Bories E, Pesenti C, Caillol F, Delpero JR. Pancreatic endocrine tumors: a large single-center experience. Pancreas 2009;38:936-40. [PMID: 19672207 DOI: 10.1097/MPA.0b013e3181b365db] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 566 |
Silvain C. Manifestations cliniques et diagnostic échoendoscopique des tumeurs endocrines digestives. Médecine Nucléaire 2009;33:689-694. [DOI: 10.1016/j.mednuc.2009.08.008] [Reference Citation Analysis]
|
| 567 |
Figueiredo FA, Giovannini M, Monges G, Bories E, Pesenti C, Caillol F, Delpero JR. EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endosc 2009;70:907-14. [PMID: 19640525 DOI: 10.1016/j.gie.2009.05.020] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 568 |
Zimmer V, Schilling MK, Buecker A, Lammert F, Raedle J. Chronic diarrhea responding to proton pump inhibitors: a clinical sign of Zollinger-Ellison syndrome. Am J Med 2009;122:e9-e10. [PMID: 19854317 DOI: 10.1016/j.amjmed.2009.06.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 569 |
Yacoub M, Laban E, Taris M, Debiais C, Jamet C, Levillain P. Classification et aspects anatomopathologiques des tumeurs endocrines digestives. Médecine Nucléaire 2009;33:680-688. [DOI: 10.1016/j.mednuc.2009.09.001] [Reference Citation Analysis]
|
| 570 |
Yoo SH. Secretory granules in inositol 1,4,5-trisphosphate-dependent Ca2+ signaling in the cytoplasm of neuroendocrine cells. FASEB J 2010;24:653-64. [PMID: 19837865 DOI: 10.1096/fj.09-132456] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 571 |
Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol 2009;6:419-28. [DOI: 10.1038/nrclinonc.2009.82] [Cited by in Crossref: 81] [Cited by in F6Publishing: 92] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 572 |
Murugesan SV, Varro A, Pritchard DM. Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 2009;29:1055-68. [PMID: 19226290 DOI: 10.1111/j.1365-2036.2009.03976.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 573 |
Goldman JA, Blanton WP, Hay DW, Wolfe MM. False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2009;7:600-2. [PMID: 19245850 DOI: 10.1016/j.cgh.2009.02.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 574 |
Abood GJ, Go A, Malhotra D, Shoup M. The Surgical and Systemic Management of Neuroendocrine Tumors of the Pancreas. Surgical Clinics of North America 2009;89:249-66. [DOI: 10.1016/j.suc.2008.10.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 575 |
Weber HC. Gastrointestinal regulatory peptides: . Current Opinion in Endocrinology, Diabetes and Obesity 2009;16:45-6. [DOI: 10.1097/med.0b013e3283223d2c] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
